Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.
This phase II trial will use Dabrafenib and/or Trametinib to enhance treatment for people with thyroid cancer who no longer respond to radioactive iodine (a standard treatment for people with this type of cancer)
Cancer type : Thyroid
This phase II study is testing the effectiveness of a new treatment combination (sotorasib, carboplatin-pemetrexed, and bevacizumab-biosimilar) for people with non-small cell lung cancer whose cancer has a specific type of gene mutation called KRAS G12C
Cancer type : Non-Small Cell Lung Cancer
This phase II study is trying to determine whether combining valproic acid (sodium valproate) to targeted therapy (panitumumab or cetuximab) is more effective than compared targeted therapy alone in people with RAS wild type metastatic bowel cancer
Cancer type : Colorectum
This phase I trial is trying to understand how safe and tolerable a new targeted cancer drug is for patients with B-Cell Non-Hodgkin's Lymphoma, and whether it is better given alone or in combination with another targeted cancer drug
Cancer type : Blood
This phase II study is evaluating how safe and effective targeted therapy (olaparib) is alone, and in combination with immunotherapy (durvalumab) is as neoadjuvant therapy in people with BRCA mutations and early stage HER2-negative breast cancer
Cancer type : Breast
This phase III trial is comparing the safety and effectiveness of an immunotherapy drug (Atezolizumab) and a chemotherapy drug (Paclitaxel), given in combination with the investigator's choice of standard chemotherapy, for the treatment of stage II or stage III triple negative breast cancer (TNBC)
This phase I study is seeking to evaluate the safety of increasing radioactive dose levels of 131I-TLX101 when given in addition to best standard of care treatment in people with newly diagnosed glioblastoma
Cancer type : Glioblastoma (GBM)
This phase III study is evaluating how safe and effective targeted therapy (gedatolisib) plus hormone therapy (fulvestrant), with or without additional targeted therapy (palbociclib) is in the treatment of advanced HR+, HER2- breast cancer who have had prior therapy
This phase III trial is trying to understand the effectiveness of a hormone therapy in men requiring radiation therapy for localised prostate cancer that has a high risk of coming back after treatment
Cancer type : Prostate
This phase III trial is trying to find the recommended dose of a targeted therapy that may benefit patients who have high-risk smouldering multiple myeloma
Cancer type : Multiple Myeloma
This phase II trial is trying to understand whether using a type of immunotherapy (Nivolumab) before starting standard chemotherapy will have a different effect on reducing tumour size for patients with early stage triple negative breast cancer, compared to if the immunotherapy and chemotherapy were given at the same time
This phase III study is measuring how well a new hormone therapy (imlunestrant) works compared to standard hormone therapy (tamoxifen, anastrozole, letrozole, or exemestane) in people with early breast cancer that is ER+ and HER2-
This phase III trial is comparing the effectiveness of giving immunotherapy (PD-1 inhibitors) intermittently as opposed to continuously, for the treatment of metastatic melanoma
Cancer type : Melanoma (Skin)
This phase II trial aims to assess the safety of two types of immunotherapy (nivolumab and relatlimab) in combination with chemotherapy, to determine if it will improve survival outcomes for people with untreated Stage IV or recurrent non-small cell lung cancer, compared to using one type of immunotherapy (nivolumab) and chemotherapy for the treatment of people with this type of cancer
Cancer type : Lung
This Phase II trial is evaluating the combination of an immunotherapy (Pembrolizumab) and a targeted therapy (Denosumab) for the treatment of advanced clear cell renal cell carcinoma (ccRCC)
Cancer type : Urinary System
This phase II trial is using an oral drug (Cabozantinib) to treat patients with locally advanced or metastatic clear cell renal cell carcinoma who have previously received or are unable to receive immunotherapy
This phase III trial is comparing a type of targeted therapy with a novel hormonal therapy (NHT) in men who have previously received one NHT for their castration resistant prostate cancer that has spread to other parts of the body
This Phase II/III trial is trying to determine whether a genetic test called “circulating tumour DNA” is an effective way to decide the specific type and duration of chemotherapy patients with localised pancreatic cancer should receive post-surgery
Cancer type : Pancreas
This phase III trial is trying to determine whether targeted therapy (Sacituzumab Govitecan-hziy) is more effective than chemotherapy (Docetaxel) in people with advanced or metastatic non-small cell lung cancer who have had previous treatment
This Phase II trial is trying to understand the effectiveness of a new targeted therapy (ARX788) in people with HER2-positive metastatic breast cancer who have not responded to other targeted therapies (T-DM1, T-DXd, Tucatinib)
This phase III study is trying to understand whether targeted therapy (tucatinib) works better than placebo when given with other drugs (trastuzumab and pertuzumab) to treat people with HER2-positive breast cancer.
This phase II study is evaluating the effectiveness of chemotherapy (paclitaxel or docetaxel) combined with targeted therapy (pertuzumab and trastuzumab), followed by surgery, followed by further treatment with targeted therapy or chemotherapy, in people with HER2-positive, ER-negative, Node-negative early breast cancer
This study is assessing the benefit of using a type of local ablative therapy (which could include surgery or radiation therapy) on top of standard of care treatment for people with colorectal cancer
Cancer type : Bowel
This phase III trial is testing different combinations of targeted therapy in people with locally advanced non-small cell lung cancer that has not progressed on prior chemoradiotherapy treatment and is unable to be surgically removed
This phase III study is comparing how safe and effective an alkylating drug (lurbinectedin) is alone, or when combined with chemotherapy (irinotecan), compared to chemotherapy alone (irinotecan or topotecan) in people with relapsed small-cell lung cancer
Cancer type : Small Cell Lung Cancer
This phase III study is measuring how well a new hormone therapy (imlunestrant) works compared to standard hormone therapy (exemestane or fulvestrant) and combination therapy (imlunestrant + abemaciclib) in people with ER+/HER2- breast cancer
This phase III trial is evaluating an oral prostate cancer treatment (Apalutamide) in patients with high risk, localised or locally advanced prostate cancer who are eligible for surgery
This phase II trial is trying to determine the effectiveness of a targeted cancer drug (ribociclib) at slowing down the growth of prostate cancer cells
This phase III trial is trying to assess whether using a single type of immunotherapy or a combination of two types of immunotherapy will improve survival outcomes for people with renal cell carcinoma that has been surgically removed, when compared to current standard-of-care (active monitoring)
This Phase III study is trying to understand the safety and effectiveness of immunotherapy (adagloxad simolenin) on improving outcomes for those with early stage, high risk triple negative breast cancer
This phase III trial is comparing the safety and effectiveness of a hormone therapy drug called Giredestrant with other types of hormone therapy for the treatment of stage 1-3 ER positive and HER2 negative breast cancer
This phase II trial is trying to find out if treatment with a targeted cancer therapy (alpelisib) and a chemotherapy (fulvestrant) increases survival compared to a chemotherapy (capecitabine) alone in men and women with ER+, HER2- breast cancer with a PIKC3A mutation
This phase III study is trying to determine whether adding targeted therapy (abemaciclib) to hormone therapy (abiraterone) in combination with steroids (prednisolone or prednisone) prolongs the time before prostate cancer gets worse
This phase III trial is tyring to determine whether an accerated two-week treatment of BEP chemotherapy is as effective as receiving the standrard three-week cycle, for patients with metastatic germ cell tumours
Cancer type : Germ cell tumour
This phase III trial is examining personalised radiation therapy for low-risk early breast cancer
This phase I/II trial will begin to understand how safe, well tolerated and effective a combination therapy is for the treatment of BRAF-mutant melanoma that has spread to other parts of the body
This phase II trial is comparing alternating chemotherapy and standard of care for patients whose colorectal cancer has spread to other parts of the body
This trial is comparing three different types and combinations of targeted therapy for the treatment of papillary renal cell carcinoma that has spread locally or to distant locations in the body
This trial is evaluating the addition of a targeted cancer drug (Magrolimab) to chemotherapy (using Nab-Paclitaxel or Paclitaxel) for the treatment of people with triple negative breast cancer that has spread to other parts of the body
This phase III study is investigating whether adding a new targeted therapy (CC-92480) to the combination treatment of targeted therapy and steroids (carfilzomib and dexamethasone) improves the effectiveness of treating multiple myeloma
This phase III trial is comparing maintenance therapy with two oral drugs (Olaparib and Cediranib), versus Olaparib as a maintenance therapy alone, in patients with relapsed ovarian cancer
Cancer type : Female Reproductive System
This phase III study is evaluating whether targeted therapy (telisotuzumab vedotin) is more effective than chemotherapy (docetaxel) in people with non-small cell lung cancer
This Phase III trial is trying to understand how safe and effective it is to combine targeted therapy (tafasitamab plus lenaliomide) with chemotherapy (R-CHOP) for the treatment of people with diffuse large B-cell lymphoma, compared to using chemotherapy (R-CHOP) alone
This phase III trial is evaluating the effectiveness of targeted therapy (fuzuloparib), compared to a placebo, in combination with hormone therapy and steroids (abiraterone acetate and prednisone [AA-P]) in people with metastatic castration-resistant prostate cancer
This phase III study aims to simplify the administration of a targeted therapy (amivantamab), by assessing a new formulation and administration method, for the treatment of non-small cell lung cancer
This phase III trial is evaluating an oral drug (Erdafitinib) for the treatment of advanced urothelial cancer, compared to standard treatment with chemotherapy or immunotherapy agents
This phase II trial is evaluating the combination of three immunotherapy drugs (Atezolizumab, Bevacizumab and Cobimetinib) in patients diagnosed with High Grade Serous Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer
This phase II/III trial is comparing four widely used chemotherapy regimens for patients with primary refractory and recurrent Ewing Sarcoma
Cancer type : Sarcoma
This phase I/II trial is evaluating how safe and effective targeted therapy (ramucirumab) is when combined with chemotherapy (cyclophosphamide and vinorelbine), compared to chemotherapy alone, in children and young adults with desmoplastic small round cell tumours (DSRCT)
Cancer type : Soft Tissue Sarcoma
This phase I/II trial is trying to understand how safe a type of targeted drug therapy is in order to determine an appropriate amount to use alone or in combination with other drugs in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer
This Phase II is trying to understand safe and effective a new cancer drug (ZN-c3) is in people with recurrent or persistent uterine serous carcinoma
Cancer type : Uterus
This phase III study is trying to determine whether having chemotherapy before surgery is more effective than surgery alone in people with dedifferentiated liposarcoma and leiomyosarcoma
This phase II study is evaluating the effectiveness of pelvic chemoradiation therapy, followed by chemotherapy (carboplatin and paclitaxel), with or without immunotherapy (tislelizumab), in people with endometrial cancer who have had surgery
Cancer type : Endometrium
This phase II study is investigating how safe and effective it is to administer heated (42 degrees Celsius) versus normal temperature (37 degrees Celsius) chemotherapy during surgery for people with epithelial ovarian, fallopian tube or peritoneal cancer
This phase II/III study is comparing the effectiveness of a new medicine (BI 907828) with chemotherapy (doxorubicin) in people with dedifferentiated liposarcoma
Cancer type : Liposarcoma
This phase III trial is evaluating how safe and effective immunotherapy (pembrolizumab) compared to chemotherapy (carboplatin and paclitaxel) is in people with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who have not had prior systemic therapy
This phase II/III study is assessing how safe and effective a new oral drug (unesbulin), compared to a placebo, is when given in combination with chemotherapy (dacarbazine) in people with inoperable, metastatic, relapsed or refractory leiomyosarcoma
Cancer type : Leiomyosarcoma
This phase III study is evaluating how safe and effective a targeted therapy (trilaciclib) compared to a placebo is, when given before chemotherapy (gemcitabine and carboplatin), in people with locally advanced or metastatic triple-negative breast cancer
This phase III study is comparing the effectiveness of a combined treatment of targeted therapy (sacituzumab govitecan-hziy) and immunotherapy (pembrolizumab), with a combined treatment of immunotherapy (pembrolizumab) and the physician's choice of chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) in people with advanced or metastatic triple negative breast cancer that expresses programmed cell death ligand 1 (PD-L1)
This phase II/III study is comparing the effectiveness of chemotherapy (nab-paclitaxel + gemcitabine) with or without a new cancer drug (SBP-101) in people with metastatic cancer of the pancreas
This phase I/II study is evaluating how safe and effective combining three targeted and immuno-therapies (nivolumab, relatilmab + bevacizumab) is, compared to the combination of two therapies (nivolumab + bevacizumab), in people with untreated, advanced or metastatic liver cancer
Cancer type : Liver
This phase I/II study is investigating how safe and effective LBL-007 plus Tislelizumab is when given in combination with targeted therapy (bevacizumab) and chemotherapy (capecitabine), compared to bevacizumab + capecitabine alone, in people with bowel cancer
This phase III trial is trying to determine if extended post-radiation chemotherapy will improve survival outcomes in patients with newly diagnosed glioblastoma
Cancer type : Brain and Spinal
This Phase II trial is trying to understand how safe and effective immunotherapy (avelumab) is in combination with chemotherapy (carboplatin and paclitaxel) and radiotherapy in people with operable oesophageal and gastro-oesophageal junction cancer
Cancer type : Stomach
This phase II trial is evaluating how safe and effective the combination of chemotherapy (Brentuximab vedotin) and donor lymphocyte infusions is in treating people with Hodgkin lymphoma that has relapsed or persists after an allogeneic stem cell transplant
Cancer type : Hodgkin's Disease (Hodgkin's Lymphoma)
This phase III trial is evaluating the survival benefit from using concurrent chemoradiation with and without targeted therapy for the treatment of small cell lung cancer
This phase III trial is evaluating an immunotherapy in combination with pre-treatment (neoadjuvant) chemotherapy and post-treatment (adjuvant) hormone therapy for the treatment of ER+/HER2- breast cancer
This phase III study is seeking to understand whether targeted therapy (tucatinib + trastuzumab) plus combination chemotherapy (mFOLFOX6) works better than standard of care treatment regimens (such as mFOLFOX6 alone, or given with either cetuximab or bevacizumab), in people with HER2 positive colorectal cancer
This phase II trial is evaluating the effectiveness of using two targeted therapies (ipilimumab and nivolumab) in combination with intracranial stereotactic radiotherapy to treat melanoma brain metastases
Cancer type : Brain
This phase II trial aims to understand how safe and effective it is to use a combination of chemotherapy, immunotherapy and chest radiation therapy to treat extensive stage small cell lung cancer
This phase III trial is evaluating the effectiveness of administering a targeted therapy (Pembrolizumab) in combination with chemotherapy drugs (Gemcitabine and Cisplantin) before surgery to treat patients with bladder cancer
Cancer type : Bladder
This phase III trial will compare the safety and effectiveness of two targeted cancer drugs in patients with HER-2 positive, invasive breast cancer following neoadjuvant therapy
This Phase III trial is evaluating which targeted therapy (Midostaurin or Gilteritinib) is more effective when combined with chemotherapy for people with newly diagnosed Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2
This phase I trial is evaluating an investigational drug (AMG 176) in patients with Multiple Myeloma or acute myeloid leukaemia
This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body
This phase II trial is assessing the benefits of using a targeted therapy (cemiplimab) in combination with a biological therapy (RP1) to treat patients with advanced or metastatic cutaneous squamous cell carcinoma
Cancer type : Cutaneous Squamous Cell Carcinoma (CSCC)
This phase II study is evaluating how safe, tolerable and effective targeted therapy (ceralasertib) is alone, and in combination with immunotherapy (durvalumab), in people with inoperable or advanced melanoma and primary or secondary resistance to PD(L)1 Inhibition
This phase II study is evaluating safety and feasibility of combination immunotherapy (atezolizumab + tiragolumab) alone, or in combination with platinum-based chemotherapy, as treatment prior to surgery in people with previously untreated locally advanced non-small cell lung cancer
This phase III trial is evaluating whether targeted therapy, alone or in combination with chemotherapy, is more effective than standard care in patients with metastatic colorectal (bowel) cancer
This Phase III study is comparing how effective VRd induction (bortezomib, lenalidomide and dexamethasone) therapy when it is followed by either immunotherapy (cilta-cel) or a combination of lenalidomide and dexamethasone in people with newly diagnosed multiple myeloma
This phase I study is evaluating how safe, tolerable and effective a new drug (XmAb24306) is in combination with immunotherapy (cevostamab) in people with relapsed or refractory multiple myeloma who have had prior treatment
This phase I trial is evaluating the investigational drug, venetoclax, in combination with chemotherapy for the treatment of Acute Myeloid Leukaemia (AML)
Cancer type : Acute Myeloid Leukaemia
This phase I trial is evaluating the combination of a new intravenous drug (S64315) and an oral chemotherapy drug (venetoclax) in patients with Acute Myeloid Leuakemia (AML)
This phase III trial is testing the addition of a targeted therapy drug to treatment for previously untreated patients with intermediate-very high risk myelodysplastic syndromes (MDS)
Cancer type : Myelodysplasia
This is the master protocol for the INTERCEPT study, which is a multi-arm treatment trial for people with acute myeloid leukaemia
This phase II/III trial is evaluating the safety and effectiveness of adding an oral targeted therapy to a standard chemotherapy/targeted therapy combination, in patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer
This Phase III trial is trying to understand the safety and effectiveness of targeted therapy (trastuzumab emtansine) in combination with immunotherapy (atezolizumab) in people with locally advanced or metastatic breast cancer
This trial is assessing different combinations of treatment with standard care for people with metastatic colorectal cancer
This phase II study is evaluating how safe and effective combination immunotherapy (atezolizumab + tiragolumab) is alone, or in addition to chemotherapy, as neoadjuvant therapy in people with previously untreated locally advanced non-small cell lung cancer
This phase III study is trying to understand how safe and effective a targeted therapy (elranatamab) is alone, or in combination with another targeted therapy (daratumumab), compared to combination therapy (daratumumab, pomalidomide and dexamethasone) in people with multiple myeloma
This phase III study is comparing the effectiveness of targeted therapy alone (tivozanib) to targeted therapy plus immunotherapy (tivozanib + nivolumab) in people with advanced kidney cancer who have had prior treatment
Cancer type : Renal cell carcinoma
This phase III study is evaluating how safe and effective combination targeted therapy (Encorafenib and Binimetinib), compared to a targeted therapy combined with a placebo (Binimetinib and placebo), is in people with melanoma who have had prior surgery
This Phase III trial is evaluating the effectiveness of a targeted therapy (Sacituzumab Govitecan-hziy) compared to chemotherapy (paclitaxel, docetaxel or vinflunine) in people with bladder cancer that is unable to be treated with surgery
Cancer type : Urothelial
This trial is trying to understand if radiotherapy could work as an effective treatment for patients with breast cancers that have had partial response to prior treatment
This Phase I/II trial is trying to understand how safe and tolerable a new targeted therapy drug (EMB-06) is in people who have multiple myeloma that has come back or is resistant to other treatment
This trial will assess how safe, tolerable and effective a new targeted therapy (AZD0466) is on its own and in combination with other cancer treatments, in people with advanced Non-Hodgkin Lymphoma
This trial will determine how safe and effective Avelumab (an immunotherapy) is as a maintenance treatment for people with advanced urothelial carcinoma who showed no progression following first-line chemotherapy treatment
This phase II study is seeking to determine how safe and tolerable, and what the best dose level is, of targeted therapy (magrolimab) in addition to further targeted therapy (bevacizumab) plus combination chemotherapy (FOLFIRI) in people with advanced, metastatic bowel cancer who have had previous treatment
This phase I/II study is trying to determine the effectiveness of administering a targeted therapy (AMP945), prior to chemotherapy (gemcitabine and nab-paclitaxel), in people with pancreatic cancer
This phase II trial is comparing the safety and effectiveness of a specialised form of radiotherapy (radioligand therapy, 177Lu-PSMA-617) given in combination with chemotherapy, versus chemotherapy alone, for patients with newly diagnosed prostate cancer
This Phase III trial is evaluating how safe and effective a targeted therapy (talzoparib) is in combination with hormone therapy (enzalutamide), compared to a placebo, in people with DDR-deficient metastatic castration-sensitive prostate cancer
This phase II study is evaluating how safe and effective multiple biomarker-selected treatments are in people with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal cancer.
This phase II study is seeking to demonstrate that treatment with a new targeted therapy (BMS-986012) in combination with chemotherapy (carboplatin + etoposide) and immunotherapy (nivolumab) is safe, tolerable and more effective than treatment with chemotherapy and immunotherapy alone in people with newly diagnosed, extensive-stage small cell lung cancer
This phase II trial is evaluating a new oral drug (CB-839) in combination with cabozantinib (a different oral drug), compared to cabozantinib alone in patients with advanced or metastatic renal cell carcinoma
This phase Ib/III trial is examining the effectiveness and safety of using a novel targeted therapy (Ipatasertib) in combination with another targeted therapy (Palbociclib) and chemotherapy (Fulvestrant) to treat advanced unresectable or metastatic breast cancer
This phase III trial is comparing the safety and effectiveness of a targeted therapy and standard chemotherapy for the treatment of patients with high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube cancer
This phase III trial is trying to determine whether the combination of two immunotherapy drugs (nivolumab and ipilimumab) is effective in preventing cancer recurrence in patients with renal cell carcinoma, who have had part or all of their kidney removed
This phase III trial will evaluate the safety and effectiveness of a type of immunotherapy, given in combination with chemotherapy (Arm A) or a type of targeted therapy (Arm B), in patients with multiple myeloma who have got worse or not responded to earlier treatment
This trial is evaluating the process of using tumour-derived DNA (ctDNA) results as a way of tailoring treatment (in this case, chemotherapy) for patients with locally advanced rectal cancer
Cancer type : Rectum
This phase III study is evaluating how safe and effective targeted therapy (itolizumab) is, compared to a placebo, in people with acute graft versus host disease
Cancer type : Graft versus Host disease
This trial is evaluating the effectiveness of a combination of targeted therapies (Nivolumab and Trametinib), with or without immunotherapy (Ipilimumab) to treat patients with recurrent metastatic colon or rectum cancer
This Phase II trial is evaluating combinations of targeted therapies (enoblituzumab, retifanlimab and tebotelimab) in people with recurrent or metastatic squamous cell carcinoma of the head and neck
Cancer type : Head and neck
This phase III study is comparing the effectiveness of two different combinations of targeted therapies (acalabrutinib + venetoclax versus venetoclax + obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma
This phase I/II study is evaluating the effective a new treatment (MBG453) alone, and in combination with another treatment (azacitadine), in people with progressive acute myeloid leukaemia
This phase II trial is evaluating the addition of an immunotherapy drug following long-course chemo-radiotherapy in patients with a locally advanced rectal cancer that is able to be surgically removed
This phase III trial is trying to determine whether it is more or less effective to use an oral targeted therapy alone or in combination with a type of chemotherapy for the treatment of advanced non-small cell lung cancer
This phase III trial is comparing a new oral therapy (Selpercatinib) with a standard treatment in patients with advanced non-small cell lung cancer
This phase I/II trial is evaluating the effectiveness and safety of a new targeted therapy (DZD9008) to treat advanced recurrent Non-small Cell Lung Cancer with EGFR or HER2 mutations
This phase I study is trying to understand how safe, tolerable and effective a new anti-cancer drug (BLYG8824A) is in people with colorectal cancer.
This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with malignant pleural mesothelioma
This phase I/II study is evaluating how safe and effective a new cancer drug (AZD2936) is in people with advanced or metastatic non-small cell lung cancer
This phase II is evaluating the effective of combination therapy (encorafenib, cetuximab and pembrolizumab) compared to immunotherapy alone (pembrolizumab) in people with previously untreated metastatic bowel cancer
This phase III study is evaluating how safe and effective different therapies (including alectinib, entrectinib, pralsetinib, and durvalumab) are in people with non-small cell lung cancer with eligible biomarker status
This phase III trial is evaluating E7777 as an intravenous treatment for patients with persistant and recurrent Cutaneous T-cell Lymphoma
Cancer type : T-Cell Lymphoma
This phase I/II trial is testing an immunotherapy alone and in combination with other anti-cancer treatments in patients with multiple myeloma who have got worse or not responded to earlier treatment
This phase II trial is evaluating the combination of two anti-cancer therapies (Venetoclax and Daratumumab) and a steroid (Dexamethasone), with or without (Bortezomib) chemotherapy in patients with Multiple Myeloma
This phase III trial is comparing the use of an oral cancer drug (Lenalidomide) alone and in combination with chemotherapy (Selinexor) and a corticosteroid (Dexamethasone) in patients with newly diagnosed multiple myeloma who are currently undergoing Autologous stem cell transplant
This phase I trial will evaluate different doses of a new cancer drug (RO7425781) for the treatment of multiple myeloma patients who cannot tolerate other treatment options or for whom no standard treatment is available
This Phase I trial is evaluating how safe and tolerable a targeted therapy (cevostamab) is in people with relapsed or refractory multiple myelomoa
This phase III trial is comparing the safety and effectiveness of two combinations of treatment for patients who have not yet received treatment for chronic lymphocytic leaukaemia
This Phase I trial is seeking to understand the recommended dose of a targeted therapy (BGB-16673) in people with B-Cell Malignancies
This phase I study is assessing how safe, tolerable and effective targeted therapy (mosunetuzumab) is in people with relapsed or refractory chronic lymphocytic leukaemia
Cancer type : Chronic Lymphocytic Leukaemia
This phase II trial is evaluating how effective a treatment of immunotherapy (pembrolizumab), followed by chemotherapy, and then followed with more immunotherapy is in people with newly diagnosed classical Hodgkin lymphoma
This phase III trial aims to evaluate the effectiveness of two targeted therapy-chemotherapy combinations in patients with Diffuse Large B-cell Lymphoma
This phase 1b/2 trial is evaluating the effectiveness of two targeted therapies (venetoclax and obinutuzumab) in combination with an immunotherapy (lenaliomide) to treat follicular lymphoma
Cancer type : Follicular Lymphoma
This phase I/II trial is evaluating a new type of immunotherapy (CTX110) in patients with B-Cell malignancies (Non-Hodgkin Lymphoma) that have got worse or not responded to prior treatment
This phase I trial is evaluating a new targeted cancer drug in patients with Non-Hodgkin's Lymphoma who have got worse or not responded to prior treatment
This phase I trial is trying to determine the best dosing level of a targeted therapy drug (BGB-11417), and assess its effectiveness both by itself and in combination with another targeted therapy (Zanubrutinib)
This Phase I/II trial is trying to understand how safe and tolerable a targeted therapy drug (glofitamab) is in combination with chemotherapy in people with higher-risk Diffuse Large B-Cell Lymphoma or High Grade B-Cell Lymphoma
This phase I trial is trying to understand how safe and tolerable a new targeted therapy (NKX019) is in people with relapsed or refractory non-Hodgkin lymphoma, chronic lymphocytic leukaemia or B-cell acute lymphoblastic leukaemia
This phase II study is assessing how safe and affective a new targeted therapy (AZD4573) is in people with either relapsed or refractory peripheral T-cell lymphoma or classical Hodgkins lymphoma
This phase I dose escalation study is seeking to determine the best dose level, safety and effectiveness of intravenous (IV) and/or subcutaneous (SC) dosing schemes of combination treatment (RO7443904, Glofitamab, Obinutuzumab and/or Tocilizumab) in people with relapsed or refractory B-cell non Hodgkin lymphoma
This phase I/II study is seeking to determine the safety and best dose level of a new drug (GB5121) in people with relapsed or refractory central nervous system lymphoma
Cancer type : Lymphoma
This phase I dose-escalation study is seeking to determine the appropriate dose level of two types of targeted therapies (talazoparib and pidnarulex) in people with metastatic, castration-resistant prostate cancer
This early phase I study is assessing the feasibility of treatment with targeted therapy (AB-218) prior to surgery in people with IDH1 mutated brain cancer (glioma)
Cancer type : Glioma
This phase I/II study is seeking to determine the appropriate dose level of Radium-223 when given in addition to combination therapy (177Lu-PSMA-I&T) in people with metastatic, castration-resistant prostate cancer
This phase I/II study is evaluating how safe and effective treatment with [161 Tb]Tb PSMA I&T is in men with metastatic castration-resistant prostate cancer
This phase I study is seeking to determine the effectiveness and appropriate dose level of a new drug (JNJ-75276617) in combination with other drugs (venetoclax and/or azacitidine) in people with acute myeloid leukaemia
This Phase II trial is comparing the effectiveness of a chemotherapy drug (Olaparib) alone and as part of a combination therapy in patients with recurrent ovarian, fallopian tube or primary peritoneal cancers that have homologous recombination repair defects
This phase II trial is trying to understand whether adding high precision radiotherapy to chemotherapy and surgery will improve treatment outcomes for patients with pancreatic cancer
This phase I trial is evaluating the safety of an oral drug (GDC-9545) when it is given alone or in combination with other therapies (Palbociclib and/or LHRH Agonist) in patients with a ER+ breast cancer that has spread to other parts of the body
This phase I trial is trying to understand how safe, effective and well tolerated a new oral cancer drug is, in combination with chemotherapy, for the treatment of patients with ovarian, peritoneal or fallopian tube cancer
This phase I trial is evaluating the safety and tolerability of a new type of immunotherapy, given alone or with standard of care treatment, in patients with PD-L1 non-small cell lung cancer
This phase III trial will assess an adjuvant immunotherapy in children and adults who have completed surgery for Stage IIB/C melanoma and have a high risk of their cancer coming back
This phase III trial is trying to understand how well three targeted cancer drugs work on their own or together to treat patients with EGFR+ non-small cell lung cancers that have spread to other parts of the body
This phase I/II trial is trying to understand how much targeted therapy is required and if it is safe to use for the treatment of B-cell lymphoma that have got worse, not responded or come back on prior treatments
This phase I trial is assessing a new targeted therapy (BI 836880 in combination with BI 754091) in patients with non-small cell lung cancer that has spread to other parts of the body and whose cancer has gotten worse on or after first line treatment
This phase Ib/IIa trial is evaluating the safety and effectiveness of a drug designed to enhance the effectiveness of other treatments (ATX-101) when combined with platinum-based chemotherapy (carboplatin/pegylated liposomal doxorubicin [ACD]) in people with platinum-sensitive, recurrent ovarian, fallopian tube or primary peritoneal cancer
This phase III study is comparing the effectiveness of different immunotherapies (ociperlimab, tislelizumab and durvalumab), combined with concurrent chemoradiation therapy, in people with previously untreated, locally advanced non-small cell lung cancer
This phase II trial is evaluating how safe and effective a targeted therapy (Mirvetuximab Soravtansine) in people with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression
This trial is trying to understand how safe and well tolerated a new form of targeted therapy is, in people with B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia that has got worse or not responded to previous treatment
This phase I/II trial is trying to understand how safe and tolerable a targeted therapy drug (epcoritamab) is when combined with standard of care treatments, including chemotherapy, steroids and other targeted therapy drugs, in people with B-cell Non-Hodgkin Lymphoma
This phase I trial is assessing simultaneous radiotherapy and immunotherapy (with durvalumab) in patients with relapsed Diffuse Large B Cell Lymphoma
This Phase II trial is trying to understand the effect of chemotherapy (obinutuzumab and atezolizumab) with or without radiotherapy in people with advanced follicular lymphoma
This phase I trial will assess how safe and tolerable a new intravenous cancer treatment is in Acute Myeloid Leukaemia, Non-Hodgkin Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukaemia patients who have not responded to prior treatment for their cancer
This phase I trial is trying to find a safe and tolerable dose of a new intravenous treatment for multiple myeloma patients who have not responded to prior treatment
This phase III study is comparing the effectiveness of targeted therapy (sacituzumab govitecan-hziy) with the physician's choice of chemotherapy (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) in people with advanced or metastatic triple-negative breast cancer
This phase III trial is testing the combination of two targeted cancer drugs (Ruxolitinib and Navitoclax) to see if it is better than using one targeted cancer drug (Ruxolitinib) to treat people with myelofibrosis
This phase III study is trying to understand the effectiveness of immunotherapy (magrolimab) versus placebo, in combination with targeted therapy and chemotherapy (venetoclax and azacitidine) in people with newly diagnosed, previously untreated acute myeloid leukaemia
This trial aims to analyses the use of tumour suppressing medication in children with relapsed or refractory tumours or synovial sarcoma
This phase II study is assessing how safe and effective different combinations of immunotherapy (magrolimab, pembrolizumab, and zimberelimab) is, with or without chemotherapy (5-FU + platinum chemotherapy, or docetaxel) in people with head and neck squamous cell carcinoma
This phase III study is comparing the effectiveness of immunotherapy (patritumab deruxtecan) with chemotherapy in people with metastatic or locally advanced non-small cell lung cancer with EGFR-activating mutation
This phase I/II study is evaluating how safe and effective a new targeted therapy (AZD5305) when given in combination with new hormonal agents (enzalutamide, abiraterone acetate or darolutamide) in people with metastatic prostate cancer
This phase III study is evaluating different methods of administered targeted therapy (isatuximab) when given in additional to combination therapy (pomalidomide and dexamethasone) in people with relapsed or refractory multiple myeloma who have had previous treatment
This phase II study is evaluating how effective targeted therapy (darovasertib) is people with occular (uveal) melanoma who are planned to undergo surgery
Cancer type : Melanoma (Ocular)
This phase III study is evaluating whether a combination of targeted therapies (MRTX849 and Cetuximab) is more effective than chemotherapy (mFOLFOX6 or FOLFIRI regimens) in people with advanced or metastatic colorectal cancer with KRAS G12c mutations who have had previous treatment
This phase II trial is investigating the use of local consolidation radiotherapy in men with non-metastatic, castrate resistant prostate cancer
This phase III study is comparing the effectiveness of two types of immunotherapy treatments (MK-7684A and atezolizumab) when used in combination with chemotherapy (etoposide and carboplatin or cisplatin) in people with Extensive-Stage Small Cell Lung Cancer
This phase II study is seeking to determine the appropriate dose level, safety and effectiveness of targeted therapy (Sacituzumab Govitecan-hziy) in combination with immunotherapy (pembrolizumab) or in combination with immunotherapy and chemotherapy (pembrolizumab, carboplatin and/or cisplatin) in people with advanced or metastatic non-small cell lung cancer
This phase III trial is trying to determine whether a new targeted cancer drug (selpercatinib) can safely and effectively delay non-small cell lung cancers from returning in non-small cell lung cancer patients who have already received surgery or radiation
This phase III trial is comparing the safety and effectiveness of a single drug treatment (belantamab mafodotin or blenrep) and a chemotherapy (pomalidomide plus low dose dexamethasone) for the treatment of patients with relapsed or refractory multiple myeloma
This phase III trial is investigating asprin for Dukes C and high risk Dukes B colorectal cancers
This phase III trial is combining two oral drugs (Ibrutinib and Venetoclax) for the treatment of Mantle Cell Lymphoma
Cancer type : Mantle Cell Lymphoma
This Phase I/II trial is trying to understand whether it is better to use a certain type of targeted therapy (derazantinib) alone or in combination with other types of therapy in patients with stomach or gastro-oesophageal cancer
This phase I/II trial is evaluating the addition of a new treatment (Denosumab) to standard immunotherapies for patients with metastatic melanoma
This phase I/IIb trial is trying to understand whether an adjuvant immunotherapy is safe, tolerable and effective for patients who have had a stage III or stage IV melanoma removed, but are at high risk of it coming back
This phase III trial is comparing survival outcomes for patients with high-risk cutaneous squamous cell carcinoma who are treated with adjuvant immunotherapy (cemiplimab), compared to those who are treated with a placebo, after surgery and radiotherapy
Cancer type : Skin
This phase III trial is trying determine whether the targeted therapy (Selpercatinib) is safe and more effective than current standard targeted therapies (Cabozantinib or Vandetanib) in patients with advanced thyroid cancer
Cancer type : Head and Neck
This phase I/II trial is assessing how safe and tolerable a variety of immunotherapy-based treatment combinations are in people with locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer, or esophageal cancer
This phase I/II trial is evaluating the safety and effectiveness of an immunotherapy combined with a type of radionuclide therapy or external beam radiation therapy in patients with Merkel Cell Carcinoma that has spread to other parts of the body
Cancer type : Merkel cell
This phase II trial is trying to understand how safe and effective a targeted therapy drug (NIS793) is with and without another targeted therapy drug (spartalizumab) in combination with chemotherapy (gemcitabine/nab-paclitaxel), compared with chemotherapy alone in people with untreated metastatic pancreatic ductal cancer
This phase II trial is evaluating how effective and well tolerated an an adjuvant immunotherapy is in patients with stage I-III Merkel Cell Carcinoma
This phase III trial is comparing an experimental drug with a standard therapy for the treatment of Anaemia caused by low- to intermediate- risk Myelodysplastic Syndrome
This phase I trial is trying to understand the safety and activity of a new targeted therapy drug (belvarafenib) by itself, and in combination with other targeted and immunotherapy drugs, in people with NRAS-mutant advanced melanoma
This phase II study is trying to understand the effect of a combination of two immunotherapies (evorpacept and pembrolizumab), compared to pembrolizumab alone, in people with head and neck squamous cell carcinoma
This phase II trial is trying to understand the effectiveness of immunotherapy (Pembrolizumab) and chemotherapy (Cisplatin/Carboplatin, 5FU) with or without targeted therapy (Evorpacept) in people with head and neck squamous cell carcinoma
This phase III study is evaluating the effectiveness of immunotherapy (ipilimumab and nivolumab) followed by the surgical removal of lymph nodes, compared to the standard upfront removal of lymph nodes followed by immunotherapy (nivolumab alone), in people with stage III melanoma
This phase III study is comparing the effects of 3 years versus 5 years of treatment with a targeted cancer drug (imatinib) in people with gastrointestinal stromal tumours (GIST)
Cancer type : Gastrointestinal stromal tumors (GISTs)
This phase III study is evaluating how effective a new immunotherapy drug (IO102-IO103) is in combination with another immunotherapy drug (pembrolizumab), compared to pembrolizumab alone, in people with previously untreated, advanced melanoma
This phase II trial is trying to understand the safety and potential impact of adding radiotherapy to standard hormone therapy in patients with castration resistant prostate cancer that has not previously been treated using chemotherapy and has spread to other parts of the body
This phase I trial is evaluating the combination of an oral therapy (olaparib) and a combination therapy (177Lu-PSMA) in patients with castration resistant prostate cancer that has spread to other parts of the body and progressed on other targeted treatments
This phase III trial is trying to determine whether adding a targeted cancer drug to hormone treatment in patients with castrate sensitive prostate cancer will result in improved survival outcomes
This phase II trial is assessing the effect of adding radiotherapy (stereotactic body radiation therapy - SBRT) to the standard of care treatment immunotherapy (ipilimumab/nivolumab), compared with immunotherapy as a standard alone treatment, in people with metastatic kidney cancer
This phase II study is evaluating the effect of immunotherapy (pembrolizumab) before treatment with radiation therapy and surgery to remove the kidney, in people with cancer of the kidney
This Phase III trial is evaluating how safe and effective a combination of targeted therapies (belzutifan + lenvatinib) is compared with another targeted therapy (cabozantinib) is in peoplke with advanced renal cell carcinoma
This phase III trial is trying to understand whether to give glioblastoma patients chemotherapy as soon as possible following surgery and prior to chemoradiotherapy; and how many cycles of standard adjuvant chemotherapy to give patients after chemoradiotherapy
This phase I trial is trying to understand how safe and effective a targeted therapy (HP518) is in people with prostate cancer.
This phase II study is trying to understand whether radiation therapy (177Lu-PSMA-617) is more safe and effective alone, or in combination with immunotherapy (ipilimumab and nivolumab), in people with metastatic, castration resistant prostate cancer
This phase III study is trying to understand how safe and effective targeted therapy (selumetinib) is compared to placebo, in adults with neurofibromatosis 1 who have symptomatic, inoperable plexiform neurofibroma
This phase I study is evaluating how safe and effective a new cancer drug (RO7428731) is in people with newly diagnosed or recurrent glioblastoma
This phase II trial is evaluating the effectiveness of a targeted therapy (trametinib) in children, teenagers and young adults with neurofibromatosis type 1 (NF1) associated Plexiform Neurofibromas and Optic Pathway Gliomas
This phase I/II study is evaluating how safe and effective chemotherapy (cabazitaxel) is in combination with radiation-based treatment (177Lu-PSMA-617) in people with metastatic castration-resistant prostate cancer
This phase III trial is evaluating the safety and effectiveness of using chemo-radiotherapy with or without immunotherapy for the treatment of patients with locally advanced cervical cancer
Cancer type : Cervix
This Phase II trial is trying to understand the effect of targeted therapy (tepotinib) in people with advanced non-small cell lung cancer.
This phase I study is investigating how safe, tolerable and effective targeted therapy (trastuzumab deruxtecan) is alone, and in combination with immunotherapy (durvalumab) and chemotherapy (cisplatin, carboplatin or pemetrexed) in people with HER2-positive, advanced or metastatic, non-small cell lung cancer
This phase I study is assessing the safety and appropriate dose level of targeted therapy (venetoclax) before treatment with chemotherapy drugs (fludarabine and cyclophosphamide) in people with certain blood cancers or disorders who are planned to undergo allogenic haematopoietic stem cell transplantation
This phase I/II study is evaluating how safe and effective a new targeted therapy (SAR443579) is in people with relapsed or refractory acute myeloid leukaemia, B-cell acute lymphoblastic leukaemia, or high-risk myelodysplasia
This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD0466) is in people with blood cancers, and to also assess the interaction it has with an antifungal drug voriconazole
This phase I/II study is assessing the best dose level, safety and effectiveness of a new drug (SNDX-5613) in people with acute leukaemia
This phase III study is comparing a combined treatment of targeted therapy (blinatumomab) and low-intensity chemotherapy to standard of care chemotherapy in older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukaemia
Cancer type : Acute Lymphoblastic Lymphoma
This Phase I/II trial is evaluating an targeted therapy drug (S64315) in combination with another cancer drug (azacitdine) in people with Acute Myeloid Leukaemia
This phase II trial is evaluating the effects of a new drug on anemia, in patients who have very low, low or intermediate risk Myelodysplastic Syndromes (MDS)
This phase I trial is trying to understand how safe and tolerable a new intravenous cancer drug (RO7283420) is for the treatment of Acute Myeloid Leukaemia (AML)
In this phase II trial, patients with severe aplastic anaemia who have been treated with, but not responded to immunosuppressive therapy (IST), will receive a new drug (avatrombopag) as a potential treatment for their condition
Cancer type : Aplastic Anaemia
This phase II trial is investigating different chemotherapy combinations for the treatment of elderly patients that have Acute Myeloid Leukaemia
This phase III trial is investigating the safety and effectiveness of two types of targeted therapy in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS)
This phase III study is evaluating how effective a combined treatment of targeted therapy (venetoclax and azacitidine) is, compared to best supportive care, to improve outcomes in people with Acute Myeloid Leukaemia who have had an allogenic stem cell transplant
This Phase I trial is seeking to determine the recommended dose level, safety and effectiveness of a targeted therapy (LY3410738) in people with IDH-mutant advanced blood cancers (including acute myeloid leukaemia, myelodysplastic syndrome, chronic myelomonocytic leukaemia and myeloproliferative neoplasms) who have previously received standard therapy
This phase III trial is trying to determine whether a chemotherapy drug (Cyclophosphamide) is better than the current standard of care at preventing graft versus host disease in patients that have recently received a bone marrow transplant
This phase II trial will combine two types of chemotherapy (venetoclax and cytarabine) for the treatment of acute myeloid leukaemia that has not responded or gotten worse with prior therapies
This phase II trial is trying to determine if a new immunotherapy (Blinatumomab) can help treat patients with Acute Lymphoblastic Leukaemia
Cancer type : Acute Lymphoblastic Leukaemia
This phase I/II study is evaluating the safety, recommended dose level, and effectiveness of a new treatment (WU-CART-007) in people with relapsed or refractory T-cell acute lymphoblastic leukaemia or lymphoblastic lymphoma
This phase I trial evaluates the safety and effectiveness of engineered CAR-T cells (CD19 targeted) alone for treatment of patients with diffuse large B-cell lymphoma and in combination with targeted therapy (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
This phase I/II trial will be comparing different doses of the drug AMG 701 in patients with Multiple Myeloma
This phase I trial is evaluating an intravenously administered drug (CX-5461) for the treatment of advanced blood cancer
This phase I study is trying to understand how safe and tolerable a targeted cancer drug (trastuzumab deruxtecan) is in combination with other anti-cancer drugs in people with metastatic breast cancer
This Phase II trial is trying to determine how effective using a combination of cancer drugs (carboplatin, gemcitabine, bevacizumab and atezolizumab) is in people with early relapsed triple negative breast cancer
This phase I/II trial is evaluating various immunotherapy based treatment combinations as a way of treating patients with a Triple Negative Breast Cancer (TNBC) that has spread to other parts of the body
This phase II trial is trying to determine whether combining an anti-HER2 therapy (trastuzumab) with two immunotherapy drugs (durvalumab and tremelimumab) will improve clinical outcomes for patients that are diagnosed with advanced HER2+ breast cancer
This phase II trial is evaluating the effectiveness of delivering different combinations of hormone therapy (including letrozole, prometrium and tamoxifen) prior to surgery in postmenopausal women with early-stage breast cancer
This phase 1b trial is evaluating the effectiveness of combining three targeted therapies (palbociclib, letrozole and venetoclax) to treat patients with ER and BCL-2 positive locally advanced or metastatic breast cancer
This phase III trial is comparing the safety and effectiveness of two oral hormone therapy drugs in patients with ER+, HER2- breast cancer that has spread locally or to other parts of the body
This phase Ib/II trial aims to explore the safety, tolerability, and anti-tumour activity of a targeted cancer therapy in patients with breast cancer that has not previously been treated using chemotherapy and has spread to other parts of the body
This phase III trial is evaluating the safety and effectiveness of an immunotherapy (Nivolumab) in combination with a chemotherapy drug (Paclitaxel) in patients with ER+/HER2- breast cancer
This phase II trial is trying to understand how effective a new targeted therapy is in Hodgkin's Lymphoma patients whose cancer has got worse or not responded to previous treatment
This Phase I/II trial is evaluating how safe and tolerable a targeted cancer drug (Giredestrant) is alone, or combined with various other cancer drugs, in people with ER-positive breast cancer
This trial is trying to understand how safe and effective a new targeted therapy is on its own and in combination with a standard immunotherapy (Pembrolizumab) in people with advanced non-small cell lung cancer who have not received previous treatment
This phase Ib/III study is evaluating the safety and effectiveness of targeted therapy (bemarituzumab), compared to a placebo, when combined with chemotherapy (mFOLFOX6) and immunotherapy (nivolumab) in people with previously untreated, advanced stomach and gastro-oesophageal junction cancer with FGFR2b overexpression
This phase I study is evaluating how safe, tolerable and effective a new targeted therapy (CC-95251) is alone, and in combination with another drug (azacitidine) in people with relapsed or refractory acute myeloid leukaemia, and people with myelodysplastic syndromes
This phase I/II study is trying to understand how safe and effective treatment with a combination of targeted therapies (mosunetuzumab and tiragolumab), with or without immunotherapy (atezolizumab), is in people with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma who have received some prior treatment
This phase II study is trying to understand how safe and effective combining standard chemotherapy (mFOLFIRINOX) with immunotherapy (durvalumab) is in people with early stage pancreatic cancer who are considered suitable for surgery
This phase III trial is evaluating the safety and effectiveness of a chemotherapy in combination with a cancer treatment known as Azacitidine (Vidaza) in patients with newly diagnosed higher-risk myelodysplastic syndrome
This phase III study is evaluating how safe and effective an oral cancer drug (belzutifan), compared with a placebo, is in combination with immunotherapy (pembrolizumab) in people with kidney cancer who have had surgery
This phase III trial is trying to determine whether it is effective to give tranexamic acid (a drug that reduces heavy bleeding) to patients with Thrombocytopenia
This phase III trial is comparing the effectiveness of three different treatments in people with previously untreated, TP53 mutant, acute myeloid leukaemia: a new targeted therapy (magrolimab) combined with a hypomethylating agent which reduces the number of abnormal blood cells (azacitidine); a different targeted therapy (venetoclax) combined with the hypomethylating agent (azacitidine); and an intensive chemotherapy regimen (including cytarabine, and daunorubicin or idarubicin)
This study is evaluating the effectiveness of a procedure called irreversible electroporation, which uses electrical pulses to destroy cancer cells, in people with stage III pancreatic cancer who have received 3 months of chemotherapy
This phase III study is evaluating whether immunotherapy (pembrolizumab/vibostolimab) in combination with chemoradiotherapy followed by further treatment with immunotherapy is more effective than treatment with chemoradiotherapy followed by a different type of immunotherapy (durvalumab), in people with non-small cell lung cancer
This phase II study is trying to understand the effectiveness of combining a new drug (CEND-1), compared to a placebo, with chemotherapy (gemcitabine and nab-paclitaxel) in people with untreated metastatic pancreatic cancer
This phase II study is evaluating how safe and effective a targeted therapy (olinvacimab) in combination with immunotherapy (pembrolizumab) is in people with metastatic triple-negative breast cancer
This study is looking at circulating DNA and how it could inform adjuvant chemotherapy for recurrence-free survival in patient with stage II colon cancer
This phase III trial is comparing the effectiveness of two treatments (chemotherapy + immunotherapy, versus the best available therapy) in myelofibrosis patients who have got worse or not responded to previous treatment
This trial aims to evaluate the safety and effectiveness of a targeted cancer therapy in combination with a type of chemotherapy in multiple myeloma patients that have got worse or not responded to at least one prior treatment
This phase III trial is comparing an immunotherapy (Pembrolizumab) and a targeted therapy (Levatinib) with chemotherapy in patients with stage III or IV endometrial cancer, or in patients whose cancer has come back following prior treatment
This Phase III trial is trying to understand whether a combination of targeted therapy (Lenvatinib) and immunotherapy (Pembrolizumab) is more effective than standard care in people with metastatic colorectal cancer
This phase I trial is evaluating a targeted therapy, given orally to patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome that has got worse or not responded to prior treatment
This phase III study seeks to understand what impact a targeted therapy (Imetelstat) will have on the overall survival of people with intermediate-2 or high-risk Myelofibrosis who are not responding to other forms of treatment
This phase I/II trial has been designed to find the recommended dose of a targeted therapy drug and determine whether it is more effective than chemotherapy as treatment for multiple myeloma
This phase III trial is evaluating whether immunotherapy (pembrolizumab) versus placebo, combined with chemotherapy (paclitaxel), with or without targeted therapy (bevacizumab), is more effective in people with epithelial ovarian, fallopian tube, or primary peritoneal cancer
This trial is evaluating the effectiveness of a targeted therapy (Isatuximab) for patients with newly diagnosed multiple myeloma, who are unable to have a transplant and have had an inadequate response to treatment with lenalidomide and dexamethasone
This phase III study is evaluating how safe and effective a combined treatment of targeted therapy (alpelisib) and a different cancer drug (olaparib), compared to chemotherapy (paclitaxel or pegylated liposomal doxorubicin), is in people with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected
Cancer type : Ovary
This phase III study is evaluating whether receiving targeted therapy (imatinib) for three or five years is more effective in people with gastrointestinal stromal tumours following surgery
Cancer type : Gastrointestinal stromal tumour (GIST)
This phase I study is trying to understand the appropriate dose level and effectiveness of a new cancer drug (RO7443904) when administered with a targeted therapy (Glofitamab) in people with relapsed or refractory B-cell non-Hodgkin's lymphoma, after they have received a different targeted therapy (obinutuzumab) as pre-treatment
This Phase II trial is evaluating how safe and effective a new drug (KER-050) is alone, and in combination with targeted therapy (ruxolitinib) in people with myelofibrosis
Cancer type : Myelofibrosis
This phase I study is trying to determine the appropriate dose level of a new targeted therapy (OP-1250) in combination with another targeted therapy (palbociclib), and to determine its effectiveness, in people with ER+/HER2- advanced or metastatic breast cancer
This Phase II study is evaluating the effectiveness of a new targeted therapy (RXC004) in people with RNF43 mutation advanced or metastatic pancreatic ductal cancer or biliary tract cancer that have progressed following standard of care treatment
This phase III trial is trying to find out if a new targeted therapy (Ipatasertib) can slow the growth of advanced breast cancer when added to standard hormone therapy (Fulvestrant)
This phase I study is evaluating how safe and tolerable a targeted therapy (talquetamab) is when administered in different combinations with other cancer drugs (including carfilzomib, daratumumab, lenalidomide and pomalidomide) in people with multiple myeloma
This phase II study is trying to determine how safe and effective a new cancer drug (PHE885) is in people with relapsed and refractory multiple myeloma
This phase I/II study is evaluating how safe and effective a new targeted therapy (BGB-11417) is alone, and in combination with the targeted therapy carfilzomib and the steroid dexamethasone, in people with relapsed/refractory multiple myeloma
This phase I dose escalation and expansion study is evaluating a targeted therapy (lemzoparlimab), with or without the steroid dexamethasone, in combination with other targeted therapies (pomalidomide, carfilzomib or daratumumab) in adults with multiple myeloma
This phase I study is assessing how safe, tolerable and effective a targeted therapy (VAY736) is alone, and in combination with cancer drug lenalidomide, in people with relapsed or refractory B-cell non-Hodgkin lymphoma
This phase I/II dose escalation and expansion trial is evaluating a new immunotherapy (GEN3014) in people with relapsed or refractory multiple myeloma
This phase I study is evaluating how safe, tolerable and effective an oral drug (CC-486) is in combination with targeted therapy (venetoclax) in people with relapsed, refractory or newly diagnosed acute myeloid leukaemia
This phase II trial is trying to find out if a new immunotherapy (sabatolimab), when given in combination with other cancer treatments (azacitidine and venetoclax) is safe and has beneficial effects in people with high or very high risk myelodysplastic syndrome who are not suitable for treatment with intensive chemotherapy or a stem-cell transplant
This phase I study is trying to understand how safe and tolerable, and determine the optimal dose level, of a targeted therapy (teclistamab) when it is administered in different combinations with other cancer drugs in people with multiple myeloma
This phase I study is evaluating how safe and tolerable different targeted therapies (MBG453, NIS793 and canakinumab) are alone, or combined, in people with lower risk myelodysplastic syndromes.
This phase III trial is comparing the effectiveness of targeted therapy (pacritinib) with the physician's choice of treatment (either corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib) in people with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
This phase II trial is trying to understand whether the addition of a new drug (avatrombopag) to standard immunosuppressive therapy (IST) can effectively treat patients with severe aplastic anaemia who have not had prior treatment
This phase I trial is trying to determine the recommended dose level, and understand how safe and effective, a new targeted therapy (ETH-155008) is in people with relapsed or refractory B-cell Non-Hodgkin's Lymphoma, chronic lymphocytic leukaemia, small lymphocytic lymphoma and acute myeloid leukaemia
This Phase III trial is evaluating the effectiveness of targeted therapy (tafasitamab), compared with a placebo, is when combined with other cancer drugs (lenalidomide and rituximab) in people with relapsed or refractory follicular lymphoma or marginal zone lymphoma
This Phase I/II trial is evaluating how safe, tolerable and effective a targeted therapy (BGB-11417) is when combined with azacitidine (an anti-cancer drug) in people with acute myeloid leukaemia and myelodysplastic syndrome
This Phase II trial is trying to understand the benefits of taking a targeted therapy (Elranatamab) alone in people with relapsed or refractory multiple myeloma
This phase I/II study is trying to understand how safe and effective a new targeted therapy (CC-92480) is when administered alone, or in combination with steroids (dexamethasone) in people with relapsed or refractory multiple myeloma
This phase I trial is evaluating how an oral drug (Enasidenib) works on single doses of other drugs in patients with Acute Myeloid Leukaemia that have an Isocitrate Dehydrogenase 2 (IDH2) mutation
This phase I trial is combining a new drug (blinatumomab) with a commonly used immunotherapy drug (pembrolizumab) for the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This phase I trial is evaluating the safety and effectiveness of an investigational therapy (BTCT4465A) alone and in combination with an immunotherapy drug (Atezolizumab) in patients with B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia who have got worse or not responded to treatment
This phase III trial is comparing the effectiveness of two targeted therapies as a first line treatment for newly diagnosed Acute Lymphoblastic Leukaemia (ALL) in combination with reduced-intensity chemotherapy
This phase III trial is comparing a type of immunotherapy, called CAR-T therapy, with two forms of standard treatment for multiple myeloma
This phase III trial is evaluating a chemotherapy-steroid combination as maintenance therapy for transplant-eligible multiple myeloma (MM) patients who are undergoing single autologous stem cell transplantation (ASCT) as part of front-line therapy
This phase II trial is trying to determine whether it is safer and more effective to use an oral targeted therapy alone or as a combination treatment for myelofibrosis
This phase III trial is evaluating the safety and effectiveness of an immunotherapy drug in combination with chemotherapy, compared to chemotherapy on its own, in patients with metastatic renal cell carcinoma
This phase II trial is evaluating the effectiveness and safety of chemotherapy (Mfolfirinox) and stereotactic radiotherapy in people with locally advanced pancreatic cancer
This phase III trial is trying to determine how well an investigational drug (NKTR-214) works when combined with an immunotherapy drug (Nivolumab) for the treatment of previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread
This phase III trial is trying to understand how safe and effective combining three types of targeted therapy (pirtobrutinib, venetoclax and rituximab) is, compared to a combination of two targeted therapies (venetoclax and rituximab) in people with chronic lymphocytic leukaemia or small lymphocytic lymphoma that have previously had treatment
The aim of this trial is to compare the use of robotic surgery with laparoscopic ('keyhole') surgery for the treatment of right sided colon cancer
This phase III trial is evaluating and comparing different treatment programs, including chemotherapy and targeted therapy, in people with liver cancer
This phase I trial is trying to measure the dose of a new oral therapy (JNJ-67856633) as a possible treatment for people with B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia, who have gotten worse or not responded to other treatments
This phase III trial is trying to understand how safe and effective immunotherapy (atezolizumab) in combination with targeted therapy (cobimetinib and vemurafenib), compared to a placebo in combination with targeted therapy, is in people with previously untreated BRAFv600 mutation-positive metastatic or locally advanced melanoma
This phase III trial is trying to compare the effectiveness of two types of targeted therapies (Lorlatinib and Crizotinib) at prolonging the progression-free survival in people with advanced ALK-positive Non-Small Cell Lung Cancer
This Phase II trial is evaluating the drug pembrolizumab (commonly used in immunotherapy) as a treatment for patients with newly diagnosed Hodkgin Lymphoma
This phase III trial is evaluating how effective 4-weekly injections of the drug Eplontersen, compared with a placebo, is in people with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Cancer type : Amyloidosis
This phase I trial is trying to determine whether it is safe to give the drug Nivolumab before and in combination with the drug Rituximab, in patients who have previously untreated Follicular Lymphoma
This phase III trial is comparing an oral drug (BGB-3111) with a combined treatment of Bendamustine and Rituximab, in patients with previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This phase I/II trial is evaluating the effectiveness of a new targeted therapy (KRT-232) combined with another targeted therapy (acalabrutinib) in people with relapsed or refractory diffuse large B-cell lymphoma and chronic lymphocytic leukaemia
This phase Ib/II trial is trying to understand how safe and effective a combined treatment of two targeted therapies (TL-895 and KRT-232) is in adults with FLT3 mutated Acute Myeloid Leukaemia
This phase III trial has been designed to evaluate the addition of two cancer treatments (venetoclax in combination with azacitidine) to standard care, compared with standard care on its' own as a maintenance therapy for adult's with acute myeloid leukaemia (AML)
This phase II trial is trying to understand how safe and effective a targeted therapy (nemtabrutinib) is in people with blood cancers
This phase II study is trying to understand how effective a combined treatment of targeted therapy (isatuximab and pomalidomide) and steroids (dexamethasone) (IPd) is in people with AL amyloidosis
This phase III trial is trying to determine the effectiveness of a targeted therapy (CAEL-101) combined with Standard of Care treatment, compared to a placebo combined with Standard of Care treatment, in people with May stage IIIb AL Amyloidosis that have not received prior treatment
This phase III study is trying to determine the effectiveness of targeted therapy (CAEL-101) combined with the Standard of Care treatment, compared to a placebo combined with the Standard of Care treatment, in people with Mayo stage IIIa AL amyloidosis that have not received prior treatment
This phase III trial is comparing the safety and effectiveness of two targeted cancer therapies, given in combination with a standard cancer treatment, for patients with multiple myeloma that has got worse or come back following prior treatment
This phase III trial is trying to determine whether a new self-administered therapy (Fedratinib) is safer and more effective than the current best available therapy in the myelofibrosis treatment
This phase I/II trial is evaluating how safe, tolerable and effective a new targeted therapy (APG-2575) is when combined with other treatment regimens (Pd or DRd) in people with relapsed or refractory multiple myeloma and immunoglobin light chain amyloidosis
This phase II trial is evaluating how safe and effective a combination of immunotherapy treatments (DPX-Survivac and Pembrolizumab) is both with and without chemotherapy (cyclophosphamide) is in people with relapsed or refractory Diffuse Large B-Cell Lymphoma
This Phase I/II trial is investigating the appropriate dose and effectiveness of two anticancer drugs (CN1 and CN401) in adult patients with relapsed or refractory peripheral T-cell lymphoma
This Phase III trial is evaluating how safe and effective targeted therapy (Trastuzumab deruxtecan (T-DXd)) is in patients with advanced or metastatic HER2-positive breast cancer that has or has not spread to the brain.
This phase II trial is evaluating an oral chemotherapy drug (Venetoclax) in participants with Chronic Lymphocytic Leukaemia (CLL)
This phase I trial is evaluating an oral drug (N-methyl-pyrrolidone) in patients with relapsed Myeloma
This phase I/II trial is evaluating an immunotherapy combination (MK-4280 and Pembrolizumab) in patients with Hodgkin Lymphoma, Non-Hodgkin Lymphoma or B-Cell Lymphoma
This phase I trial is evaluating the safety and effectiveness of two targeted therapy drugs, each given in combination with chemotherapy for the treatment of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) that has got worse or not responded to prior treatment
This phase I trial is evaluating two drugs (one oral and one intravenous) in Acute Myeloid Leukaemia (AML) patients who have got worse or not responded to treatment
This phase II trial is evaluating Obinutuzumab alone and in combination with a new oral drug (BGB-3111) for the treatment of non-Hodgkin follicular lymphoma that has got worse or not responded to prior treatment
This phase I trial is testing a new oral drug (MAX-40279) for the treatment of Acute Myelogenous Leukaemia (AML)
This phase I trial is trying to understand how the body reacts to a targeted therapy drug (zanubrutinib) with administered in combination with enzyme inhibitors (cytochrome P450 A) in people with B-Cell malignancies
This Phase I/II trial is trying determine the effectiveness of a targeted therapy drug (KRT-232) in combination with chemotherapy (cytarabine and decitabine) in people adults with acute myeloid leukaemia
This phase II trial is trying to understand the safety and effectiveness of a targeted therapy drug (AFM13) in people with CD30-positive T-cell lymphoma
This Phase III trial is trying to understand the effect of a new immunotherapy (MBG453) in combination with chemotherapy (azacitidine) compared with azacitidine and a placebo in people with intermediate, high or very high risk myelodysplastic syndrome or chronic myelomonocytic leukaemia-2
This phase II trial is evaluating an investigational antibody therapy (KappaMab) in combination with lenalidomide (a chemotherapy drug) and dexamethasone (a steroid) for the treatment of relapsed Multiple Myeloma
This phase III trial will assign patients with follicular lymphoma to a certain type of treatment using a PET-scan and assess overall outcomes associated with treatment
This phase III trial is trying to understand whether it is safer and more effective to combine chemotherapy and targeted therapy for the treatment of mantle cell lymphoma, or to use targeted therapy alone, in patients who are not eligible for a stem cell transplant and have not received prior treatment
This phase III trial is trying to determine the benefit of adding an immunotherapy drug (Ibrutinib) to Rituximab treatment in patients who have been diagnosed with Follicular Lymphoma and not yet received treatment
This phase III trial is evaluating chemotherapy intensification in Hodgkin Lymphoma patients who receive less radiotherapy
This phase I trial is investigating a new drug (BGB3111) for the treatment of B-Cell Lymphomas
This phase III trial is trying to improve maintenance therapy for patients with stage 3B or 4 non-small cell lung cancer who have remained stable or responded to first-line treatment. It will compare immunotherapy alone and in combination with an oral targeted therapy.
This Phase II trial is evaluating how effective two different combinations of treatments including anticancer drugs, chemotherapy and immunotherapy, are at treating classical Hodgkin lymphoma
This phase 3 trial is comparing the effectiveness of concurrent chemoradiotherapy (CCRT) followed by different combinations targeted therapies (nivolumab, ipilimumab or durvalumab) for the treatment of locally advanced non-small call lung cancer
This Phase I trial is evaluating the safety of a targeted therapy drug (IGM-2323) in people with relapsed or refractory Non-Hodgkin Lymphoma
This trial aims to assess the safety and effectiveness of combined anti-cancer treatment in patients with previously untreated diffuse large B-cell lymphoma
This phase II trial is comparing the safety and effectiveness of a new, experimental treatment and standard of care in patients with acute myeloid leukaemia in complete first remission
This phase II trial is assessing the safety and effectiveness of using targeted therapy and chemotherapy to treat fit patients with previously untreated mantle cell lymphoma, with or without a stem cell transplant and further maintenance therapy
This phase I/II study is trying to determine the appropriate dosing of a targeted therapy (AZD4573) alone, and then evaluate how effective it is when combined with another targeted therapy (acalabrutinib), in people with advanced blood cancers
This phase III trial is evaluating the safety and effectiveness of a targeted therapy in patients with chronic lymphocytic leukaemia
This phase II/III trial is comparing preoperative chemradiotherapy with preoperative chemotherapy for patients with resectable gastric cancer
This phase II study is trying to determine if standard chemotherapy induction therapy followed by immunotherapy (pembrolizumab) will be effective in maintaining life expectancy with minimal side effects for people with primary central nervous system lymphoma
This phase III trial is trying to determine if giving neoadjuvant, then adjuvant immunotherapy will prolong survival in patients with early stage non-small cell lung cancer
This phase III trial is trying to understand how safe and effective immunotherapy (pembrolizumab) is when combined with chemotherapy in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
This Early Phase I trial is trying to understand how safe and tolerable a targeted therapy (APG-2575) is in people with cancers of the blood, bone marrow and lymph nodes
This phase II trial is evaluating how well combinations of chemotherapy (UH-3 and ICE/Cyclo/Tropo) work in treating children, adolescents and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilm's Tumour (DAWT) or relapsed favourable histology Wilm's Tumour (FHWT)
Cancer type : Wilm's tumour
This study is evaluating the impact of new cancer treatments in both newly diagnosed and relapsed rhabdomyosarcoma patients; it will determine whether changing the duration of maintenance therapy affects outcome; and whether changes to dose, extent and timing of radiotherapy improve outcomes and quality of life for patients
This phase II/III trial is trying to understand how effective using a combination of cancer treatments (including chemotherapy, targeted therapy and immunotherapy) to target specific genes is when treating children with acute lymphoblastic leukaemia (ALL) and acute lymphoblastic lymphoma (LLy)
This phase I trial is testing a cancer drug that works by switching on genes to stop cancer growth, to see if it is a suitable treatment for children whose brain cancer has not responded to, or has gotten worse on, prior treatment
This phase II trial is evaluating how safe and effective targeted therapy (DAY101) is in children, adolescents and young adults with recurrent or progressive, low-grade glioma with a known BRAF alteration
This phase II trial is evaluating the effects of different combinations of chemotherapy (UH-3 and ICE/Cyclo/Topo) in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's Tumour (DAWT) or favourable histology Wilm's Tumour (FHWT) that has come back (relapsed)
This phase II trial is evaluating whether stopping targeted therapy (tyrosine kinase inhibitors) affects treatment-free remission in people with chronic phase myeloid leukaemia
Cancer type : Chronic Myelogenous Leukaemia
This phase II trial is trying to understand how safe and effective targeted therapy (axatilimab) is at three different dose levels in people with recurrent or refractory active chronic Graft versus Host disease
This phase III trial is comparing an oral drug (Rucaparib) with standard treatment in patients who have metastatic castration-resistant prostate cancer
This phase III trial is evaluating how effective administering immunotherapy (CG0070) through a tube directly into the bladder is to treat non-muscular invasive bladder cancer who have had previous immunotherapy (BCG)
This Phase III trial is comparing the effectiveness of two targeted therapies (mosunetuzumab and rituximab) when they are combined with another cancer drug (lenalidomide) in people with follicular lymphoma who have received previous treatment
This phase II trial is trying to understand whether treatment responses for people with Chronic Myelomonocytic Leukaemia can be improved by targeting certain gene mutations with certain cancer drugs (such as lenzilumab, azacitidine and sodium ascorbate)
Cancer type : Leukaemia
This Phase III trial is seeking to find out if one targeted therapy (zanidatamab), when given with chemotherapy (capecitabine plus oxaliplatin or 5-fluorouracil plus cisplatin) with or without another targeted therapy (tislelizumab), is safe and works better than a different targeted therapy (trastuzumab) plus chemotherapy, in patients with HER2-positive cancers of the stomach or oesophagus
This phase III trial is trying to understand how safe and effective an adjuvant therapy is compared to active surveillance in patients that have had their hepatocellular (liver) cancer removed or destroyed and who have a high risk of their cancer coming back
This trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia
This phase II/III trial is looking at different treatment protocols for children and adolescents with Langerhans Cell Histiocytosis
Cancer type : Langerhans Cell Histiocytosis
This Phase III trial is managing the treatment (which may involve chemotherapy, radiotherapy and/or surgery) of people with low and intermediate risk patients with neuroblastoma
Cancer type : Neuroblastoma
This Phase III trial is evaluating how well targeted therapy (blinatumomab) works in combination with chemotherapy in treating people with newly diagnosed, standard risk B-lymphoblastic leukaemia or B-lymphoblastic lymphoma.
This Phase III trial is assessing whether adding a targeted therapy (inotuzumab ozogamicin) to post-induction chemotherapy for people with high risk B-cell acute lymphoblastic leukaemia improves outcomes
This phase I trial is testing a new oral drug in patients with ER+, HER2- breast cancer
This phase III trial is trying to find the best combination of cancer drugs (SAR439859 + palbociclib, compared to letrozole + palbociclib) to improve survival in patients with ER+, HER2- advanced breast cancer who have not received prior treatment for advanced disease
This phase II/III trial is evaluating the effectiveness of a novel immunotherapy (Bintafusp Alfa) in combination with the standard of care chemotherapy (Gemcitabine and Cisplatin) to treat patients with locally advanced or metastatic Biliary Tract Cancer
Cancer type : Bile duct
This Phase II trial is evaluating how safe and effective a new targeted therapy (valemetostat tosylate) is in patients with relapsed or refractory peripheral T-cell lymphoma, including adult T-cell leukaemia/lymphoma patients
This Phase I study is trying to understand the recommended dose, safety and effective of a new targeted therapy (PSB202) in people with previously treated B-cell cancers
This Phase I/II trial is evaluating how safe and tolerable a new oral targeted therapy (AZD4205) is in people with peripheral T-Cell lymphoma
This phase II trial is testing a new targeted therapy in patients with B-cell Non-Hodgkin Lymphoma, whose cancer has got worse or will not respond to other treatments
This Phase I trial is seeking to determine the recommended dose, safety and tolerability of a new hormone therapy (OP-1250) in combination with targeted therapy (palbociclib) in people with advanced or metastatic HR+ and HER2- breast cancer
This phase I/II trial will begin to understand how effective a combination therapy (BelaMafKd) is for the treatment of relapsed or refractory multiple myeloma
This Phase III trial is evaluating how safe and effective a targeted therapy (tazemetostat) is in combination with other cancer drugs (lenalidomide and rituximab) in people with follicular lymphoma who have had at least one prior treatment of chemotherapy, immunotherapy or chemoimmunotherapy
This Phase III trial is evaluating the effectiveness of a targeted therapy (LOXO-305) compared to other similar targeted therapies (ibrutinib, acalabrutinib, and zanubrutinib) in people with mantle cell lymphoma
This Phase II trial is trying to understand how effective chemotherapy (docetaxel) is when delivered intermittently, compared to continuously, in men with metastatic castration-resistant prostate cancer
This phase III trial is testing the oral drug, regorafenib, for the treatment of refractory and advanced gastro-oesophageal cancers
This Phase II trial is evaluating how safe and effective a targeted therapy (ABBV-927) is when combined with chemotherapy (mFFX) both with or without another targeted therapy (budigalimab), compared to mFFX alone, in adults with untreated metastatic pancreatic cancer
This Phase III trial is trying to understand effective different combinations of targeted and immunotherapies (Tislelizumab, Ociperlimab, and Pembrolizumab) are in people with non-small cell lung cancer
This phase III trial will evaluate the combination of two types of targeted therapy to determine if it will be safe and effective to treat people that have been diagnosed with locally advanced or metastatic non-small cell lung cancer that has progressed (got worse) following previous chemotherapy
This phase III trial is trying to understand whether it is more or less effective to use hormone therapy alone or in combination with a targeted cancer drug for the treatment of advanced HR+/HER2- breast cancer that has gotten worse or come back on prior treatment
This Phase I/II trial is evaluating the efficacy of targeted therapy (derazantinib) alone, or in combination with immunotherapy (atezolizumab) in people with advanced bladder (urothelial) cancer
This phase III trial is evaluating whether radiotherapy and LHRH agonist are a more effective treatment when also combined with apalutamide (hormone therapy) in people with prostate cancer
This Phase I trial is evaluating how safe and effective combining to targeted therapies (binimetinib and encorafenib) is in adolescents with BRAF V600-mutant advanced or metastatic melanoma
This Phase I trial is evaluating the effectiveness of a new cancer treatment (PTM-101) in people with boderline resectable or locally advanced pancreatic cancer
This phase I trial aims to understand how safe, well tolerated and effective a new targeted cancer drug (BMS-986158) is in people with DIPSS-intermediate or high risk Myelofibrosis, when given alone or in combination with targeted cancer treatment (Ruxolitinib or Fedratinib)
This trial is comparing the effect of having adjuvant therapy on its own, or in combination with axillary treatment, in women with early stage breast cancer
This phase III trial is looking at the effect of adding mitomycin C (a chemotherapy drug) to standard treatment, in patients with invasive bladder cancer
This phase I trial is evaluating the safety and dose of a new oral drug (CPI-818) in patients with T-Cell Lymphoma who have got worse or not responded to prior treatment
This phase II trial is evaluating the combination of revlimid (chemotherapy) and rituximab maintenance therapy in the treatment of patients with Follicular Lymphoma
This Phase II trial is trying to understand how safe and effective an immunotherapy drug (Belantamab mafodotin) is in people with multiple myeloma that Anti-CD38 antibody targeted treatments have been unsuccessful for
This Phase I trial is trying to understand how safe, tolerable and effective different doses of a targeted therapy drug (APG-2575) is alone, or in combination with other treatments such as chemotherapy (including ibrutinib or rituzimab) in people with Waldenström Macroglobulinemia
Cancer type : B-Cell Non Hodgkin Lymphoma
This Phase II trial is trying to understand the effectiveness of an oral drug (PAX-1) in combination with standard of care treatment in people with newly diagnosed or recurrent glioblastoma
This Phase III trial is evaluating how safe and effective combinations of immunotherapy (pembrolizumab) and targeted therapies (lenvatinib, quavonlimab, belzutifan) are in people with advanced clear cell renal cell carcinoma
This phase I/II trial is looking at the most appropriate treatment approaches for patients with newly diagnosed multiple myeloma, taking into consideration patient frailty (weakness)
This Phase II trial is evaluating how safe and effective a targeted therapy (BNT111) is when used by itself or combined with immunotherapy (cemiplimab) in people with anti-PD1-refractory or relapsed melanoma
This phase II trial is measuring the safety and recommended dose of an immunotherapy drug (GSK2857916) in combination with another cancer drug (Bortezomib or Lenalidomide) and a steroid for the treatment of multiple myeloma that has got worse or is not responsive to other treatments
This phase I trial is trying to understand how a new intravenous drug works, and if it is safe and tolerable to use, in the treatment of patients with multiple myeloma
This phase I trial is evaluating an intravenous drug (BFCR4350A) in patients with multiple myeloma, who have progressed or not responded to prior treatment
This Phase I trial is evaluating how safe and tolerable an experimental targeted therapy (NKX101) is in people with acute myeloid leukaemia or myelodysplastic syndromes
This Phase II study is trying to understand the effectiveness of a targeted therapy drug (cobolimab) in combination with another type of targeted therapy (dostarlimab) and chemotherapy (docetaxel) in people with advanced non-small cell lung cancer
This phase III trial is comparing the effectiveness of two different combinations of chemotherapy and targeted therapy drugs (Trifluridine/tipiracil hydrochloride and Bevacizumab versus Capecitabine and Bevacizumab) for treating patients with metastatic colorectal cancer, who are not candidates for intensive therapy.
This Phase III trial is trying to understand how safe and effective a combination of chemotherapy (pemetrexed and platinum chemotherapy) and immunotherapy (pembrolizumab) is with and without a targeted cancer drug (lenvatinib) is in people with metastatic nonsquamous non-small cell lung cancer
This Phase III trial is trying to understand how effective a new anti-cancer drug (HBI-8000) is in combination with immunotherapy (Nivolumab) in people with advanced melanoma
This trial is trying to determine the best way of delivering radiation therapy to the breast tissue of people diagnosed with invasive, Grade 1, 2 or 3 breast cancer, before surgery
This Phase III trial is trying to determine if a combined treatment of targeted and immunotherapy drugs (regorafenib and nivolumab) is more effective than the current standard chemotherapy treatments in people with advanced gastro-oesophageal cancer
This trial is testing how safe and effective a new oral targeted therapy (Ponatinib) is when combined with chemotherapy in the treatment of children, adolescents and young adults diagnosed with Acute Lymphoblastic Leukemia
This phase II trial is evaluating the repeat administration of radiotherapy to a previously exposed region of the body, with the aim of treating people with Diffuse Intrinsic Pontine Glioma that is getting worse or has recently come back
This phase II trial is trying to determine the effectiveness and dosing level of a targeted therapy drug (TL-895) in people with Myelofibrosis
This phase II trial is evaluating a new form of immunotherapy (xentuzumab) to see whether it enhances combination treatment with a chemotherapy drug (Everolimus) and hormone therapy drug (Exemestane) in patients with hormone receptor positive (HR+), HER2- breast cancer that has spread to other parts of the body
This phase II trial is evaluating the combination of nivolumab (an immunotherapy drug) and two other drugs (BNC105 or BBI608) in patients with colorectal cancers that have spread to other parts of the body and have failed prior therapies
This phase III trial is combining a targeted cancer treatment and immunotherapy treatment to see how this combination impacts survival outcomes for people whose renal cell carcinoma (a type of cancer) has spread to other parts of the body
This Phase III trial is comparing an anti-HER2-antibody drug with standard of care therapy in patients with pre-treated, HER2-positive breast cancer that has spread to other parts of the body
This trial will evaluate different combinations of targeted cancer treatment in patients with clear cell renal cell carcinoma (ccRCC)
This phase II trial is comparing the effect of a chemotherapy drug (Temozolomide) alone and in combination with an immunotherapy drug (Nivolumab) for the treatment of elderly patients with a newly diagnosed glioblastoma
This trial will evaluate the safety and effectiveness of different treatment combinations in patients with newly diagnosed, advanced clear cell renal cell carcinoma
This phase II/III trial is comparing two intravenous drugs (Irinotecan liposome injection and Topotecan injection) in patients with small cell lung cancer who have gotten worse after first line therapy
This phase III trial is trying to determine whether a smaller surgical margin will be effective in the removal of primary cutaneous melanoma and improve patient quality of life
This phase IV trial is trying to determine if giving an iron infusion to iron-deficient colorectal cancer patients who are anaemic versus not anaemic will improve their physical fitness for planned surgery
This trial aims to evaluate a radiation-based treatment in men with prostate cancer who are undergoing surgery for their cancer
This phase III trial is evaluating an immunotherapy (tabelecleucel) for the treatment of Epstein-Barr Virus-associated post-transplant lymphoproliferative disease in the setting of solid organ transplant after failure of rituximab or rituximab plus chemotherapy
This phase III trial is evaluating different types of response-based chemotherapy in treating newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome in younger patients with Down syndrome
This phase I trial is trying to find a safe and effective dose of a new targeted cancer drug, to treat patients with B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia who have got worse, not responded or are unable to receive other treatment
This phase III trial will add a type of immunotherapy to chemotherapy treatment in patients with recurrent or metastatic squamous cell carcinoma of the anal canal, to see if it is more or less effective than using chemotherapy on its' own
Cancer type : Anus
This phase I trial is testing two different ways to give an immunotherapy drug (isatuximab) to patients with Multiple Myeloma, who have got worse or not responded to prior treatment
This phase I trial will begin to understand how safe and tolerable an intravenous cancer drug (ABBV-467) is for the treatment of multiple myeloma in patients who have not responded or got worse on previous treatment
This phase I trial is trying to determine the safety and recommended dose of an immunotherapy, combined with standard of care treatment, in patients with newly diagnosed multiple myeloma
This phase I trial is evaluating the safety and effectiveness of a new oral drug (TG-1701) for patients with B-cell malignancies that have not responded or gotten worse with prior treatments
This phase II trial is evaluating an oral drug (KRT-232) for the treatment of patients with myelofibrosis who are no longer benefiting their current treatment with a JAK inhibitor
This phase I trial will evaluate whether stereotactic ablative radiotherapy (SABR) is a safe and effective treatment option for patients with non-small cell lung cancer (NSCLC) whose cancer is large and/or has spread to the nearby lymph nodes
This phase I trial is studying a new oral cancer drug in combination with immunotherapy or chemotherapy for the treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
This phase I/II trial is evaluating the safety and effectiveness of 5 new drugs in combination treatment for people with myelofibrosis
This phase III trial is evaluating the safety and effectiveness of using chemo-radiotherapy with and without immunotherapy for the treatment of patients with muscle-invasive bladder cancer
This phase IV trial will evaluate the safety and effectiveness of an immunotherapy, combined with chemotherapy, as first line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma
This phase I/II trial is testing the safety and effectiveness of a targeted therapy in combination with chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults
This phase III trial is evaluating the safety and effectiveness of various targeted therapy and chemotherapy combinations for the treatment of newly diagnosed, advanced ovarian cancer
This phase III trial will evaluate how safe and effective two types of immunotherapy are, compared to a placebo, for the treatment of locally advanced oesophageal squamous cell cancer
Cancer type : Oesophagus
This phase II trial is evaluating the effect of the anti-cancer drug Rucaparib in patients with metastatic castration-resistant prostate cancer
This phase III trial is evaluating two oral therapies (DCC-2618 and sunitinib) in patients with advanced gastrointestinal stromal tumours following prior treatment
This phase II trial is evaluating a combination of chemotherapy and immunotherapy treatments in patients with neuroblastoma that has come back or not responded to prior treatment
This phase III trial is comparing two induction chemotherapy treatments in children with Acute Myeloid Leukaemia (AML)
This phase II/III trial is evaluating allogenic stem cell transplatation as an optimal therapy for children and adolescents diagnosed with Acute Lymphoblastic Leukaemia (ALL)
This phase II trial is evaluating a combination of hormone treatments that may be useful for pre-surgery breast cancer treatment
This phase III trial is comparing the safety and effectiveness of different targeted therapies for the treatment of locally advanced non-small cell lung cancer
This phase II trial will test the safety and effectiveness of a targeted cancer drug, alone and in combination with immunotherapy, to see if it is better than standard of care chemotherapy in patients with head and neck cancers that have spread, come back and/or gotten worse after treatment
This phase I trial is evaluating the safety and recommended dose level of a new drug (intravenous JNJ-61186372) in patients with advanced non-small cell lung cancer (NSCLC)
This phase III trial trying to compare the relative survival of patients who receive either (i) nivolumab and ipilimumab (ii) nivolumab and chemotherapy or (iii) chemotherapy alone for the treatment of oesophageal and gastro-oesophageal junction cancers
This phase I trial is trying to understand how much immunotherapy is safe and effective for the treatment of castration-resistant prostate cancer that has spread to other parts of the body
This phase III trial is comparing two chemotherapy combinations for the treatment of advanced biliary tract cancer
This phase III trial is comparing outcomes for patients with Non-Small Cell (NSC) Lung Cancer, who are receiving second- or third- line chemotherapy with docetaxel alone and in combination with plinabulin, for advanced stage or metastatic disease
This phase II trial is testing an oral anti-cancer therapy (Brigatinib) in patients who have ALK+ non-small cell lung cancer
This phase 2 trial is assessing the clinical benefit of adding a statin (Simvastatin) to standard chemotherapy and radiotherapy to treat patients with rectal cancer before surgery
This phase II trial is evaluating an immunotherapy (zolbetuximab) in combination with chemotherapy (gemcitabine and nab-paclitaxel) in patients who have pancreatic cancer that has spread to other parts of the body
This phase 3 trial is comparing the benefit of using targeted therapies, either in combination (Nivolumab plus Ipilimumab) or alone (nivolumab) to treat patients with metastatic colorectal cancer.
This phase 3 study is evaluating the effectiveness and safety of a targeted therapy (Infigratinib) in comparison with the standard of care chemotherapy (Gemcitabine plus Cisplatin) for treatment of patients with inoperable or metastatic cholangiocarcinoma
This Phase III trial is comparing the effects of giving an oral drug (Osimertinib) alone and in combination with stereotactic radiosurgery (SRS) in patients with non-small cell lung cancer (NSCLC) that has spread to the brain
This phase III trial is trying to determine whether an immunotherapy drug (Pembrolizumab) is an effective therapy to give after surgery and radiation in patients with locally advanced cutaneous squamous cell carcinoma
This Phase III trial is evaluating an immunotherapy agent (Pembrolizumab) as a monotherapy for patients who have Renal Cell Carcinoma and have undergone a nephrectomy surgical procedure
This phase II trial is evaluating the safety and effectiveness of an immunotherapy (Pembrolizumab) in patients with high risk, non-muscle invasive bladder cancer, who have not responded to prior therapy
This is a phase I trial assessing the safety and tolerability of using immunotherapy drugs (PDR001 and /or MBG453) in combination with chemotherapy (Decitabine) to treat patients with Acute Myleoid Leukaemia or High Risk Myelodysplastic Syndrome
This phase III trial is testing a drug called BBI-608 in combination with other drugs, for patients with previously treated metastatic colorectal cancer (CRC)
This trial is testing hormone therapy, using oral (Z)-Endoxifen, as a treatment for patients with invasive breast cancer
This phase II trial is testing the safety of an immunotherapy treatment in infants with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)
This phase II trial is trying to determine the benefit of adding Bevacizumab (an intravenous drug) to chemotherapy treatment with Vinblastine, in children and adolescents with low grade gliomas
This phase I/II trial is using an oral drug (LOXO-101) as a treatment in children and adolescents with central nervous system tumours
Cancer type : Central Nervous System
This phase III trial is comparing surgery and radiation therapy in the treatment of stage I Non-Small Cell (NSC) Lung Cancer
This phase III trial is comparing two drugs (Rovalpituzumab Tesirine and Topotecan) in patients with advanced or metastatic Small Cell Lung Cancer (SCLC) that has gotten worse following front-line chemotherapy
This phase I trial is assessing the safety of administering a drug (pembrolizumab) by injection beneath the skin for the treatment of advanced melanoma
This phase II trial is testing a drug (pembrolizumab) in combination with chemotherapy and radiotherapy for the treatment of locally advanced Stage III non-small cell lung cancer that cannot be removed by surgery
This phase III trial is comparing the drug, avelumab, with platinum-based doublet chemotherapy in Non-Small Cell (NSC) Lung Cancer patients with PD-L1+ tumours
This trial is assessing the safety and efficacy of Irreversible Electroporation for the removal of prostate cancer
This phase I trial is trying to determine the recommended dose of a new drug (IMP321) when given in combination with an immunotherapy agent (pembrolizumab) for people with metastatic melanoma
This phase II trial will assess the effectiveness of different Medullablastoma treatments in patients, according to their clinical risk and molecular subtype
Cancer type : Medullablastoma
This phase III trial is comparing post-radiation chemotherapy and observation for the treatment of young people with newly diagnosed ependymomas
Cancer type : Ependymomas
This phase II trial is trying to determine whether the use of mirena, metformin or a weight loss intervention is effective in the treatment of early-stage endometrial cancer
This phase III trial is evaluating tretinoin and arsenic trioxide for the treatment of patients with newly diagnosed Acute Promyelocytic Leukemia
Cancer type : Acute Promyelocytic Leukaemia
This phase I/II trial is trying to determine how much carfilzomib (an anti-cancer drug) should be used, alone and in combination with induction chemotherapy, to treat children with Acute Lymphoblastic Leukaemia (ALL)
This phase III trial is trying to determine whether blinatumomab (a drug) is better as a consolidation therapy than standard chemotherapy for patients with Acute Lymphoblastic Leukaemia (ALL)
This phase I trial is trying to understand the safety of a new targeted therapy (PMR-116) in people with advanced solid cancers
Cancer type : Multi-Cancer
This phase I study is evaluating how safe, tolerable a new cancer drug (IOS-1002) is alone, and when given in combination with a PD-1 antibody, in people with advanced solid cancers
This phase I study is evaluating how safe and effective targeted therapy (LOXO-783) is alone, or when given with other anti-cancer therapies (such as fulvestrant, imlunestrant, abemaciclib, paclitaxel, and aromatase inhibitors) in people with advanced breast cancer or other solid cancers with a PIK3CA H1047R mutation
This phase I/II study is evaluating how safe, tolerable and effective a new drug (TYRA-300) is in people certain cancers with FGFR3 activating gene alterations
This Phase II study is trying to understand how effective a targeted therapy (trastuzumab emtansine) is in people with cancers with HER2 amplifications or mutations
This Phase II trial is evaluating how safe and tolerable a targeted therapy (entrectinib) is in people with newly diagnosed non-squamous non-small cell lung cancer an advanced solid cancers with NTRK fusions or ROS1 gene rearrangements
This phase II trial is evaluating how safe and effective a combination of two targeted therapies (vemurafenib and cobimetinib) are in people with metastatic non-squamous non-small cell lung cancer and other solid cancers with BRAF V600 mutations
This phase I trial is evaluating an intravenous drug (CK-301) in patients with select advanced cancers
This phase I/II trial is evaluating the safety and recommended dose of a combined targeted therapy (BGB-A425 and Tislelizumab) in patients with advanced solid cancers
This phase I/II study is evaluating how safe, tolerable and effective a new cancer drug (NVL-655) is in people with advanced ALK-positive (ALK+) non-small cell lung cancer, and other solid cancers
This phase I/II trial is evaluating the safety of a new oral drug using different dose levels, in patients with advanced solid cancer or Tenosynovial Giant Cell Tumor
This phase 1 trial is evaluating the effectiveness and safety of a novel immunotherapy (AK112) for the treatment of patients with advanced solid tumours
This phase II study is evaluating the effectiveness of hormone therapy (letrozole) when combined with targeted therapy (alpelisib or ribociclib) in post-menopausal women with advanced gynaecological cancers that are hormone-receptor positive
This phase I study is testing a new cancer treatment that targets the tumour marker Lewis Y ('Lewis Y Chimeric Antigen Receptor T-cell Therapy') in combination with a commonly used immunotherapy drug (nivolumab) in people with Lewis Y-expressing solid cancers
This phase I study is trying to determine how safe and effective a new cancer drug (AZD9592) is alone, and in combination with targeted therapy (osimertinib), in people with advanced solid cancers
This trial is assessing the safety and effectiveness of ATG-018 treatment in people with advanced cancer, including some types of blood cancer
This phase I/II trial is trying to determine whether it is safe to give the study drug (BMS-986249), alone and in combination with an immunotherapy (Nivolumab), to patients with advanced solid cancers
This phase I study is evaluating how safe and effective a new oral drug (GDC-1971) is when given in combination with immunotherapy (atezolizumab) in people with locally advanced or metastatic solid cancers
This Phase I trial is trying to understand how safe and tolerable a targeted therapy (T3011) is in people with advanced cancers
This phase II study is evaluating the effectiveness of an anticancer drug (larotrectinib) in people with advanced solid cancers with NTRK1-3 rearrangements
This Phase I trial is trying to understand how safe and tolerable a targeted therapy drug (VT3989) is in people with advanced pleural malignant mesothelioma or other metastatic solid tumours
This phase I/II study is evaluating how safe, tolerable and effective a new cancer drug (AZD8205) is in people with advanced or metastatic solid cancers
This phase I study is evaluating how safe, tolerable and effective a new drug (AXA-042) is in people with advanced or metastatic solid cancers, excluding brain and blood cancers
This phase III study is trying to understand how safe and effective radiation-based treatment (177Lu-Edotreotide PRRT) compared to best standard of care treatment in people with neuroendocrine tumours that originate in the stomach, intestines or pancreas.
Cancer type : Neuroendocrine tumours
This phase I study is evaluating how safe, tolerable and effective a new cancer drug (BGB-B167) is alone, and in combination with targeted therapy (tislelizumab) in people with advanced solid cancers
This phase I/II trial is trying to understand how safe, tolerable and effective a targeted therapy (AU-007), with or without immunotherapy (aldesleukin), is in people with advanced or metastatic solid cancer
This Phase I trial is evaluating how safe and effective different doses of a new targeted cancer drug (Auceliciclib) is in people with advanced solid cancers, or when given in combination with chemotherapy (temozolomide) in people with glioblastoma multiforme
This Phase I trial is evaluating appropriate dosing levels of an intratumoral therapy (within a tumour) alone, and in combination with immunotherapy (pembrolizumab) in people with advanced solid cancers
This phase I study is seeking to determine the best dose level and safety of a new targeted therapy (BAT6021) alone, and in combination with another targeted therapy (BAT1308), in people with locally advanced, recurrent, or metastatic incurable solid cancers
This phase I/II study is trying to determine the appropriate dose level, and safety, of a new targeted therapy (GB263T) in people with advanced solid cancer, including non-small cell lung cancer
This phase I/II study is trying to determine how safe and effective, and what the appropriate dose level of a new cancer drug (LM-108) alone, or in combination with targeted therapy (an Anti-PD-1 Antibody) in people with solid cancers
This phase I/II study is seeking to determine the appropriate dose level, safety and effectiveness of a new cancer treatment (HLX301) in people with locally advanced or metastatic solid cancers
This phase I study is seeking to determine the best dose level and effectiveness of a new targeted therapy (YH004) alone, and in combination with immunotherapy (toripalimab) in people with advanced solid cancers and relapsed or refractory non-Hodgkin lymphoma
This phase II study is evaluating how safe and effective chemotherapy (belzutifan) is in combination with immunotherapy (pembrolizumab) and targeted therapy (lenvatinib) in people with multiple solid cancers, including cancer of the liver, bowel, pancreas, biliary tract, endometrium and oesophagus
This phase I/II study is trying to determine the best dose level and safety of a new treatment drug (PRS-344/S095012) in people with advanced or metastatic solid cancers
This phase I trial is testing a new drug (KN046) in patients with advanced cancers who are not able to have any other standard therapies
This phase I trial is testing different chemotherapy and immunotherapy combinations in patients with advanced triple-negative breast cancer or ovarian cancer
This phase I trial is evaluating an immunotherapy and chemotherapy combination in patients with advanced gastroesophageal cancer or colorectal cancer
This phase I/II trial is trying to determine the safety and tolerability of an oral drug, repotrectinib
This phase I study is aiming to determine the best dose level and safety of a new cancer drug (IAG933) in people with advanced mesothelioma and other solid cancers
This phase I trial is evaluating how safe and effective a targeted cancer drug (ERAS-601) is alone, or when combined with another targeted therapy (Cetuximab) in people with advanced or metastatic solid cancers
This phase I trial is trying to understand how safe and tolerable a new targeted therapy drug (PF-07062119) is in people with selected advanced or metastatic gastrointestinal cancers
This phase I/II study is seeking to determine the best dose level, safety and effectiveness of a new cancer drug (NVL-250) in people with locally advanced solid cancers
This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD9574) is alone, or in combination with chemotherapy (temozolomide) in people with advanced solid cancers
This phase I trial is evaluating a new targeted therapy in patients with advanced cancers and cancers that have spread to other parts of the body
This phase II trial is trying to determine how safe and tolerable a targeted therapy is for the treatment of several different cancer types
This phase I trial will evaluate how safe and tolerable a new oral cancer drug is for the treatment of advanced solid cancers, when given alone or in combination with a type of immunotherapy
This phase I study seeks to understand the safety of a new drug (ADG126) in people with cancers that are advanced and/or have spread to other parts of the body (metastatic)
This phase Ia/Ib trial is evaluating how safe, tolerable and effective a new targeted therapy is, given alone or in combination with another targeted therapy, in patients with advanced cancer
This Phase I/II study is evaluating how safe and tolerable a new targeted therapy (GFH018) is in combination with a different targeted therapy (toripalimab) is in people with advanced solid cancers
This phase I/II study is trying to determine the best dose level, safety and tolerability of an oral targeted therapy (EO1001) in people with advanced EGFR, HER2 or HER4 positive cancer
This phase I/II trial will begin to understand how safe and tolerable a new cancer drug (D-1553) is as a monotherapy and combination treatment for people with advanced solid cancers that have a KRasG12C mutation
This phase I study is seeking to understand the appropriate dose level, safety and effectiveness of a new targeted therapy (D3S-001) in people with advanced solid cancers with the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) p.G12C mutation
This phase I study is evaluating how safe and effective a combination of two new cancer drugs (YH002 and YH001) are in people with advanced solid cancers
This phase I/II dose escalation and expansion study is trying to understand how safe and effective a new drug (TAK-280) is in people with locally advanced or metastatic cancer that is unable to be removed with surgery
This phase II trial is trying to determine the clinical benefit of using two types of immunotherapy (nivolumab combined with ipilimumab) to treat neuroendocrine cancers, biliary tract cancers, gynaecological cancers and MSI-H cancers (excluding colorectal cancer)
This phase II study is evaluating how safe and effective a new cancer drug (YH003) is in combination with targeted therapy (toripalimab), and how these drugs combine with chemotherapy, in people with metastatic melanoma and pancreas cancer
This phase I study is evaluating the effectiveness of a new targeted therapy (CLN-619) alone, and in combination with immunotherapy (pembrolizumab), in people with advanced solid cancers
This phase I study is evaluating how safe and effective a combination of two new cancer drugs (YH003 and YH001) and immunotherapy (pembrolizumab) is in people with advanced solid cancer
This phase I/II trial is evaluating how safe and tolerable a new targeted therapy (LM-302) is when combined with immunotherapy (toripalimab) in people with advanced solid cancers
This phase I trial is investigating how safe and tolerable a new targeted therapy (ATG-101) is in people with metastatic or advanced solid cancers, and mature B-cell Non-Hodgkin Lymphoma
This phase I/II study is investigating the effects of targeted therapy (BMS-986253) in combination with immunotherapy (nivolumab and/or ipilimumab) in people with advanced solid cancers
This phase I study is trying to understand how safe, tolerable and effective a new targeted therapy (PF-07248144) is alone, or combined with either hormone therapy (fulvestrant) or hormone therapy (letrozole) and another targeted therapy (palbociclib), in people with breast cancer, prostate cancer or non-small cell lung cancer
This phase 1 trial is examining the safety and effectiveness of two targeted therapies (BGB-A1217 and Tislelizumab) for the treatment of advanced solid tumours
This phase II study is evaluating the effect of targeted therapy (Sacituzumab Govitecan-hziy) in people with advanced non-small cell lung cancer, head and neck squamous cell carcinoma, endometrial cancer or small cell lung cancer
This phase I/II study is seeking to determine the best dose level, safety and effect, of a new cancer drug (DYP688) in people with metastatic ocular (uveal) melanoma
This phase II study is assessing the effect of targeted therapy (sotorasib) in adults with some advanced cancers that have KRAS G12C mutations
This phase II study is evaluating the effect of a targeted therapy (alectinib) in people with newly diagnosed metastatic non-squamous small cell lung cancer (NSCLC) or people with advanced solid cancers with ALK gene alterations
This Phase II trial is evaluating how safe, tolerable and effective targeted therapy (palbociclib) is when combined with immunotherapy (avelumab) is in people with solid cancers with activating alterations in cell cycle genes
This phase II study is evaluating the effect of a combination of targeted therapies (tucatinib plus trastuzumab) in people with advanced or metastatic solid cancers with HER2 amplifications or mutations
This phase II study is evaluating the effect of immunotherapy (tremelimumab) in people with advanced rare cancers
This phase II study aims to assess the effectiveness of vismodegib, an oral cancer drug, in people with advanced or metastatic solid cancer with PTCH1 or SMO mutations
This phase I study is evaluating how safe, tolerable and effective a new drug (XL092) is alone, or combined with immunotherapy (Atezolizumab or Avelumab) in people with inoperable, locally advanced or metastatic solid cancers
This phase I trial is trying to determine the best dose of a drug (CC-95251) given to patients alone or in combination with one of two types of targeted cancer treatments (Rituximab or Cetuximab) in patients with advanced cancers (including advanced types of blood cancer)
This phase I/II trial is testing a new intravenous drug (THOR-707) as a monotherapy (alone) and in combination with an immunotherapy in adult patients with advanced cancer that has spread to other parts of the body
This Phase I/II trial is trying to determine the safety and recommended dose of two drugs (PD-0325901 and BGB-283) given in combination for the treatment of advanced solid cancers
This phase I trial is trying to determine the recommended dose of a new intravenous therapy (GSK3745417), when given alone or in combination with a type of immunotherapy, in patients with solid cancer types
This Phase I trial is trying to determine how safe and tolerable a targeted therapy (BGB-3245) is in people with solid cancers with B-RAF genetic mutations.
This phase I trial is testing a new drug on its own and in combination with a type of immunotherapy in patients with advanced cancers that have spread locally or to other parts of the body
This phase I trial is evaluating a new targeted therapy alone and in combination with another type of targeted therapy to see if it is safe and tolerable for advanced cancer patients
This phase I trial will test how safe and tolerable a new oral cancer drug is for the treatment of patients with advanced solid cancers or cancers of the blood
This phase I trial is trying to understand if a new oral drug works and is safe for the treatment of advanced KRAS G12C mutated solid cancers that have spread to other parts of the body
This trial is evaluating individually tailored treatment plans in people with advanced cancers who are accessing targeted therapy cancer drugs through compassionate access
This Phase I/II trial is trying to determine how safe, tolerable and effective a targeted cancer drug (AZD5305) is alone, or in combination with chemotherapy (paclitaxel and carboplatin) in people with advanced solid cancers
This phase II trial has been designed to evaluate the safety and effectiveness of using targeted therapies or immunotherapy as a single agent or combination treatment in patients with advanced solid tumours that have specific genetic alteration(s)
This Phase Ib/II trial is seeking to determine the recommended dose, and then the safety and effectiveness, of a new targeted therapy (JDQ443) alone, and in combination with other targeted therapies (TNO155 and spartalizumab) in people with advanced solid cancers
This Phase I trial is trying to understand how safe and tolerable a targeted therapy (BGB-15025) alone and in combination with another targeted therapy (tislelizumab) in people with advanced solid cancers
This phase II study is evaluating how effective a combined treatment of two targeted therapies (pamiparib and tislelizumab) in people with advanced cancers that have molecular profiles consistent with homologous recombination deficiency (HRD)
This phase I study is evaluating how safe and effective a new targeted therapy (AMX 818) is alone, or in combination with immunotherapy (pembrolizumab) in people with HER2+ cancers
This phase I study is evaluating how safe, tolerable and effective a new cancer drug (BGB-24714) is alone, and in combination with chemotherapy (paclitaxel) in people with advanced or metastatic solid cancers
This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (PBI-200) is in people with NTRK-fusion-positive advanced or metastatic solid cancers
This phase I/II is investigating the appropriate dose level and effectiveness of a new cancer drug (MT-5111) in people with HER2-positive solid cancers
This phase I trial is evaluating how safe and effective targeted therapy (MK-1084) is alone in people with advanced solid cancers with KRASG12C mutation, and when it is combined with immunotherapy (pembrolizumab) in people with non-small cell cancer with KRASG12C mutation
This phase I/II trial is exploring increasing doses of a new cancer drug (YH003) in combination with a targeted therapy with the aim of identifying and evaluating maximum tolerated/recommended dose
This phase I trial is evaluating how safe and tolerable a targeted therapy (talazoparib) is in combination with radionuclide therapy (177Lu-DOTA-Octreotate) in people with metastatic pancreatic neuroendocrine cancer
This Phase III study is trying to understand the impact of Stereotactic Ablative Radiotherapy (SABR), compared to standard of care treatments in people with 4 to 10 metastatic cancer deposits
This phase I trial is evaluating how safe, tolerable and effective a targeted therapy (SHR-A1811) is in people with HER2 expressing or mutated advanced solid cancers
This Phase I trial is evaluating a targeted therapy (ALPN-202) in people with advanced solid cancers, or refractory lymphoma.
This study aims to understand the impact of anaesthesia on duration of disease free survival in patients undergoing surgery for colorectal or non-small cell lung cancer
This phase II trial is testing the effectiveness of a new oral drug (Pabinostat) in paediatric and adult patients who have an osteosarcoma, rhabdoid tumour and/or neuroblastoma that has gotten worse or not responded to prior treatment
This phase II trial is trying to determine the safety and effectiveness of a targeted treatment (Olaparib) in combination with an immunotherapy (Pembrolizumab) in adult patients who have previously been treated for advanced HRRm and/or HRD+ tumours
This phase I/Ib trial is comparing a new immunotherapy agent (CPI-006) alone and in combination with two other therapies (CPI-444 and pembrolizumab) in adults diagnosed with select advanced cancers
This phase I trial is evaluating how safe and tolerable a new biological therapy (AK127) in combination with another biological therapy (AK104 or cadonilimab) in patients with advanced or metastatic solid cancers (excluding some blood cancers)
This phase I/II trial is testing how safe and tolerable a new targeted cancer therapy is for the treatment of patients with mature B-cell blood cancer (when given in combination with the standard targeted therapy, zanubrutinib) or for patients with a type of advanced cancer (given in combination with the standard targeted therapy, tislelizumab)
This phase I/II trial is evaluating an oral drug (tazemetostat) alone and in combination with a steroid (prednisolone) for the treatment of advanced solid cancers and patients with B Cell Lymphoma
This Phase I trial is evaluating how safe and tolerable a targeted therapy drug (WM-S1-030) is in people with advanced solid cancers
This Phase I trial is evaluating how safe and tolerable a new cancer drug (ABBV-637) is alone, or in combination with chemotherapy (docetaxel) or targeted therapy (osimertinib) in in people with relapsed or refractory solid cancers
This phase I/II study is evaluating how safe and effective a combined treatment of targeted therapy (Bempegaldesleukin) and immunotherapy (Nivolumab) in children, adolescents and young adults with recurrent or treatment-resistant cancers
This phase I/II trial is evaluating how safe and tolerable targeted therapy (alectinib) is in children and adolescents with Anaplastic Lymphoma Kinase (ALK) fusion-positive solid cancers or cancers of the brain or spinal cord
This phase III trial is evaluating how well active surveillance and four different chemotherapy drugs (bleomycin, carboplatin, etoposide, or cisplatin) work in treating paediatric or adult patients with germ cell tumours
This phase I/II trial is trying to understand how safe and well tolerated a new immunotherapy is when combined with a standard immunotherapy drug in patients with advanced cancer
This phase I trial is evaluating an intravenous drug (PTX-100) in people with an advanced cancer
This phase Ib trial is trying to understand how safe and tolerable a type of targeted therapy is for the treatment of several different types of cancer
This trial is measuring the safety and maximum tolerated dose of a new experimental cancer drug (BNA035) in people with advanced solid cancers
This Phase I/II trial is evaluating how safe and tolerable a new targeted therapy (ICP-192) is in people with advanced solid cancers, gall bladder cancer or bladder cancer
This Phase I/II trial is trying to determine the recommended dose, safety and tolerability of a new targeted therapy (EMB-02) in people with advanced solid cancers
This Phase I/II trial is trying to evaluate how safe and tolerable a new cancer drug (TransCon TLR7/8 Agonist) alone, and in combination with immunotherapy (Pembrolizumab) in people with advanced or metastatic solid cancers
This phase I trial will begin to understand how safe and tolerable a combination therapy (containing a new cancer drug, IMP4297, and a type of chemotherapy) is in people diagnosed with advanced solid cancer, including small cell lung cancer
This trial is trying to understand how safe and tolerable a new oral treatment (APL-101) is for patients with non-small cell lung cancer and other advanced cancers
This Phase I trial is trying to understand how safe and effective a targeted therapy (CYH33) is in combination with chemotherapy (olaprib) is in people with advanced solid cancers that have DDR gene mutations and/or PIK3CA mutations
This trial is trying to understand how safe, well tolerated and effective a new targeted cancer drug is in patients with squamous cell carcinoma of the head and neck, non-small cell lung cancer or colorectal cancer
This study is evaluating how safe a type of targeted therapy (Lenvatinib) is for the treatment of children, adolescents, and young adults with relapsed or refractory cancer
This study aims to analyse the effectiveness of combined treatment in children and adolescents with certain high risk refractory, relapsed or progressive cancer
This phase I/II trial is trying to understand how safe and tolerable a new immunotherapy is for the treatment of advanced cancer
This phase I trial is trying to understand how safe a new targeted cancer therapy is, and how much of it to use, as a combination treatment for patients with advanced solid cancers that have spread to other parts of the body
This Phase II trial is trying to determine how safe and effective a combination therapy (with pembrolizumab and lenvatinib) is in treating patients with select advanced cancers
This phase I trial is evaluating ABBV-927 (an immunotherapy) alone and in combination with nivolumab for the treatment of advanced cancer
This phase I/II trial is testing a new oral cancer drug (LOXO-292) for the treatment of children that have advanced solid- or primary central nervous system- cancer
This phase I trial is trying to understand whether a new intravenous drug is safe and tolerable for the treatment of patients with advanced cancer
This Phase I trial is evaluating an intravenous drug (ABBV-321) in patients with advanced cancers that are associated with EGFR overexpression
This phase I trial is evaluating how safe and tolerable a new oral drug (IN10018) is, when it is given on it's own and in combination with an oral targeted therapy, for patients with uveal or NRAS-mutant melanoma that has spread to other parts of the body
This phase I/II trial is testing how safe ENB003 is as a treatment for select solid cancers, and how well it is tolerated in patients, when given alone or in combination with a type of immunotherapy (Pembrolizumab)
This phase 1 trial is evaluating the safety and effectiveness of a novel biological therapy (MK-0482) alone and in combination with a targeted therapy (pembrolizumab) to treat patients with advanced solid tumours
This phase I trial is evaluating a new immunotherapy drug (MK-7684) alone and in combination with another immunotherapy drug (Pembrolizumab) in patients with advanced solid tumours
This phase I trial is evaluating the safety and effectiveness of increasing doses of an immunotherapy drug (MK-1308) given in combination with another immunotherapy drug (Pembrolizumab) for the treatment of patients with advanced solid tumours
This early phase I trial is evaluating the safety and effectiveness of a new immunotherapy (Anti-B7-H4 Antibody, FPA150) alone and in combination with another type of immunotherapy (Pembrolizumab) in patients with select advanced cancers
This phase I/II trial is evaluating the safety and effectiveness of a combination treatment for patients with advanced pancreatic cancer or other EGFR expressing cancers
This phase I trial is evaluating an oral drug (venetoclax) with or without chemotherapy in children and young adults with relapsed or refractory malignancies
This phase II trial is assessing a type of radiotherapy treatment for patients whose cancer has spread to the brain
This phase I trial is evaluating an intravenously (in the vein) administered drug (APG-1387) in patients with advanced solid cancers or Lymphoma
This phase III trial is evaluating pembrolizumab in patients who have previously received systemic treatment for advanced hepatocellular (liver) cancer
This phase I/II trial is evaluating pembrolizumab (an immunotherapy drug) in children with advanced Melanoma, PD-L1 positive solid cancer or Lymphoma
Keyword Search
Cancer type
Trial type
Phase
Molecular targets
Tumour characteristics
Hospital
Alfred Hospital, Prahran
Austin Health, Heidelberg
Ballarat Hospital, Ballarat
Ballarat Oncology & Haematology, Ballarat
Barwon Health, University Hospital Geelong, Geelong
Bendigo Hospital, Bendigo
Border Medical Oncology, Albury
Box Hill Hospital, Box Hill
Cabrini Hospital, Malvern
Epworth Eastern, Box Hill
Epworth Freemasons, East Melbourne
Epworth Hospital, Richmond
Goulburn Valley Health, Shepparton
John Fawkner Hospital, Coburg
Maroondah Hospital, Maroondah Breast Clinic, Ringwood East
Mercy Hospital for Women, Heidelberg
Monash Health,
Northern Hospital, Epping
Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg
Peninsula & South Eastern Haematology and Oncology Group, Frankston
Peninsula Health, Frankston
Peninsula Private Hospital, Frankston
Peter MacCallum Cancer Centre, Moorabbin, Moorabbin
Peter MacCallum Cancer Centre, Box Hill
Peter MacCallum Cancer Centre, Melbourne
Peter MacCallum Cancer Centre Bendigo, Bendigo
Royal Childrens Hospital, Parkville
Royal Melbourne Hospital, Parkville
Royal Womens Hospital, Parkville
South West Healthcare, Warrnambool
St John of God, Geelong
St Vincent's Hospital, Fitzroy
Victorian Breast and Oncology Care, East Melbourne
Warringal Private Hospital, Heidelberg
Werribee Mercy, Werribee
Western Health - Sunshine Hospital, St Albans
Women's Health Research Program, Monash University, Alfred Hospital, Prahran
Use the search filters to narrow your search.
Don’t show me this again